BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242. [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001] [Cited by in Crossref: 1092] [Cited by in F6Publishing: 1017] [Article Influence: 78.0] [Reference Citation Analysis]
Number Citing Articles
1 Malmström S, Eilard A, Larsson SB, Hannoun C, Norkrans G, Lindh M. Genotype impact on long-term virological outcome of chronic hepatitis B virus infection. Journal of Clinical Virology 2012;54:321-6. [DOI: 10.1016/j.jcv.2012.04.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
2 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
3 Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011;83:1909-16. [DOI: 10.1002/jmv.22199] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
4 Li YW, Yang FC, Lu HQ, Zhang JS. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol 2016; 22(6): 1943-1952 [PMID: 26877602 DOI: 10.3748/wjg.v22.i6.1943] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
5 Sayan M, Akhan SC, Senturk O. Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies. Hepat Mon 2011;11:835-42. [DOI: 10.5812/kowsar.1735143x.1004] [Reference Citation Analysis]
6 Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, Ballanti E, Migliore A. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol. 2013;2013:410521. [PMID: 23606869 DOI: 10.1155/2013/410521] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
7 Vermehren J, Kau A, Zeuzem S. Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment. Curr Hepatitis Rep 2010;9:53-9. [DOI: 10.1007/s11901-010-0036-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
9 Fuentes Olmo J, Uribarrena Amézaga R. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]. Gastroenterol Hepatol 2011;34:492-503. [PMID: 21550145 DOI: 10.1016/j.gastrohep.2011.02.009] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int 2021;15:611-20. [PMID: 33677771 DOI: 10.1007/s12072-021-10162-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70:178-186. [PMID: 24220724 DOI: 10.1016/j.jaad.2013.08.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
12 Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother. 2014;15:1337-1349. [PMID: 24773464 DOI: 10.1517/14656566.2014.913571] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
13 Lee HJ, Seo YS, Kim DJ, Kang HS, An H, Kim JH, Cheong JY, Yim HJ, Yeon JE, Lee HS, Byun KS, Cho SW, Kim DJ, Um SH, Kim CD, Ryu HS. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B: HALF index in chronic hepatitis B patients. Journal of Gastroenterology and Hepatology 2011;26:987-95. [DOI: 10.1111/j.1440-1746.2010.06609.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
14 Kim SB, Song IH, Kim YM, Noh R, Kang HY, Lee HI, Yang HY, Kim AN, Chae HB, Lee SH, Kim HS, Lee TH, Kang YW, Lee ES, Kim SH, Lee BS, Lee HY. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6943-6950 [PMID: 23322992 DOI: 10.3748/wjg.v18.i47.6943] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hayer J, Rodriguez C, Germanidis G, Deléage G, Zoulim F, Pawlotsky JM, Combet C. Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention. J Virol 2014;88:574-82. [PMID: 24173223 DOI: 10.1128/JVI.03000-13] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
16 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
17 Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010;16:124-132. [PMID: 20339187 DOI: 10.4103/1319-3767.61244] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
18 Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol. 2009;51:1091-1096. [PMID: 19836097 DOI: 10.1016/j.jhep.2009.07.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
19 Shouval D. Focus. J Hepatol 2011;54:189-90. [PMID: 21087807 DOI: 10.1016/j.jhep.2010.10.007] [Reference Citation Analysis]
20 Jr GP, Kim JH, Suh JS, Sharp VL. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol 2010; 16(9): 1093-1096 [PMID: 20205279 DOI: 10.3748/wjg.v16.i9.1093] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
21 Viganò M, Bhoori S, Lampertico P, Donato MF, Iavarone M, Grossi G, Facciorusso A, Caccamo L, Rossi G, Colombo M, Mazzaferro V. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. Liver Int 2015;35:2187-93. [PMID: 25809541 DOI: 10.1111/liv.12835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat. 2013;20 Suppl 1:40-45. [PMID: 23458523 DOI: 10.1111/jvh.12062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
23 Khungar V, Han SH. A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep 2010;9:75-90. [PMID: 20461127 DOI: 10.1007/s11901-010-0039-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
24 Alexopoulou A, Papatheodoridis GV. Entecavir treatment in HBV-related decompensated cirrhosis. Future Virology 2011;6:1275-81. [DOI: 10.2217/fvl.11.103] [Reference Citation Analysis]
25 Ismail AM, Sivakumar J, Anantharam R, Dayalan S, Samuel P, Fletcher GJ, Gnanamony M, Abraham P. Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantification. J Clin Microbiol. 2011;49:3215-3221. [PMID: 21795507 DOI: 10.1128/jcm.00915-11] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Al-Ashqar HI, Al-Quaiz M, Dahab ST, Peedikayil MC. Entecavir for the treatment of real-life chronic hepatitis B patients: a study from Saudi Arabia. Ann Saudi Med 2013;33:119-23. [PMID: 23951584 DOI: 10.5144/0256-4947.2013.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
27 Specialist Panel on Chronic Hepatitis B in the Middle East. A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. J Viral Hepat. 2012;19:9-22. [PMID: 22187943 DOI: 10.1111/j.1365-2893.2011.01511.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
28 Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol. 2011;26:456-460. [PMID: 21332542 DOI: 10.1111/j.1440-1746.2010.06492.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 6.0] [Reference Citation Analysis]
29 Chung KH, Kim W, Kim BG, Lee HY, Jin E, Cho Y, Seo JY, Kim HY, Jung YJ, Kim JW, Jeong JB, Lee KL. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. Gut Liver. 2015;9:657-664. [PMID: 25717049 DOI: 10.5009/gnl14188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
30 Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(22): 3481-3486 [PMID: 23801842 DOI: 10.3748/wjg.v19.i22.3481] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
31 Lee S, Kwon CH, Moon HH, Kim TS, Roh Y, Song S, Shin M, Kim JM, Park JB, Kim SJ. Antiviral treatment for hepatitis B virus recurrence following liver transplantation. Clin Transplant. 2013;27:E597-E604. [PMID: 24093615 DOI: 10.1111/ctr.12212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
32 Al-Ashgar HI, Khan MQ, Aljumah A, Sanai FM, Abdo AA, Dafalla MM, Fagih MA, Bzeizi KI. Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients. Hepatol Int 2012;6:718-26. [PMID: 23936583 DOI: 10.1007/s12072-011-9319-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
33 Erhardt A, Göbel T, Ludwig A, Lau GK, Marcellin P, van Bömmel F, Heinzel-Pleines U, Adams O, Häussinger D. Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol. 2009;81:1716-1720. [PMID: 19697400 DOI: 10.1002/jmv.21588] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
34 Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322-328. [PMID: 23796869 DOI: 10.1016/j.jinf.2013.06.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
35 Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013;58:205-9. [PMID: 23159772 DOI: 10.1016/j.jhep.2012.11.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 7.5] [Reference Citation Analysis]
36 Peng C, Lai H, Li Y, Su W, Chuang P, Kao J. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012;35:458-68. [DOI: 10.1111/j.1365-2036.2011.04973.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
37 Lampertico P, Viganò M, Facchetti F, Invernizzi F, Aroldi A, Lunghi G, Messa PG, Colombo M. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant. 2011;26:2037-2041. [PMID: 21486869 DOI: 10.1093/ndt/gfr174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
38 Seth AK. HBsAg Quantification in Clinical Practice. J Clin Exp Hepatol 2012;2:75-80. [PMID: 25755408 DOI: 10.1016/S0973-6883(12)60084-X] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
40 Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014;34 Suppl 1:139-145. [PMID: 24373091 DOI: 10.1111/liv.12394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
41 Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Cecchini E, Baldelli F. Reactivation of Hepatitis B Virus Replication Due to Cytotoxic Therapy: A Five-Year Prospective Study. Tumori 2012;98:220-4. [DOI: 10.1177/030089161209800207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
43 Gramenzi A, Loggi E, Micco L, Cursaro C, Fiorino S, Galli S, Gitto S, Galli C, Furlini G, Bernardi M, Andreone P. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients: HBsAg in lamivudine-treated chronic hepatitis B. Journal of Viral Hepatitis 2011;18:e468-74. [DOI: 10.1111/j.1365-2893.2011.01473.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
44 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011;43:589-95. [DOI: 10.1016/j.dld.2010.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
45 Begini P, Cox MC, Angeletti S, Gigante E, Baccini F, Fonzo MD, Fave GD, Marignani M. Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: A case report. Scandinavian Journal of Infectious Diseases 2011;43:750-2. [DOI: 10.3109/00365548.2011.574149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int. 2012;32:622-628. [PMID: 22098684 DOI: 10.1111/j.1478-3231.2011.02663.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
47 Akbar SM, Hiasa Y, Mishiro S, Onji M. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10:1605-14. [PMID: 19496738 DOI: 10.1517/14656560903005579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
48 Yang H, Sherman M, Su J, Chen P, Liaw Y, Iloeje UH, Chen C. Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. JCO 2010;28:2437-44. [DOI: 10.1200/jco.2009.27.4456] [Cited by in Crossref: 177] [Cited by in F6Publishing: 77] [Article Influence: 14.8] [Reference Citation Analysis]
49 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012; 3(4): 49-61 [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
50 Kwon JH, Kim YS, Kim SG, Jang JW, Kim TH, Jung YK, Kwon OS. The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting. Gut Liver. 2013;7:197-205. [PMID: 23560156 DOI: 10.5009/gnl.2013.7.2.197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
51 Dan JQ, Zhang YJ, Huang JT, Chen MS, Gao HJ, Peng ZW, Xu L, Lau WY. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2013;39:865-872. [PMID: 23597497 DOI: 10.1016/j.ejso.2013.03.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
52 Giacchino R, Cappelli B. Treatment of viral hepatitis B in children. Expert Opinion on Pharmacotherapy 2010;11:889-903. [DOI: 10.1517/14656561003642006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
53 Wiegand J, Meya S, Schlaphoff V, Manns MP, Mössner J, Wedemeyer H, Tillmann HL. HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat 2010;17:631-9. [PMID: 19889141 DOI: 10.1111/j.1365-2893.2009.01220.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
54 Ren S, Wang J, Chen TL, Li HY, Wan YS, Peng NF, Gui XE, Zhu Y. Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance and Replication through Two Distinct Mechanisms. PLoS One 2016;11:e0152721. [PMID: 27023403 DOI: 10.1371/journal.pone.0152721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
55 Vassilopoulos D, Manolakopoulos S. Rheumatic manifestations of hepatitis. Current Opinion in Rheumatology 2010;22:91-6. [DOI: 10.1097/bor.0b013e328333ba5d] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
56 Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71:2511-2529. [PMID: 22141390 DOI: 10.2165/11208510-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
57 Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res 2014;14:170. [PMID: 24731689 DOI: 10.1186/1472-6963-14-170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
58 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-1149.e3; quiz e13-14. [PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007] [Cited by in Crossref: 307] [Cited by in F6Publishing: 295] [Article Influence: 30.7] [Reference Citation Analysis]
59 Mederacke I, Bremer B, Heidrich B, Kirschner J, Deterding K, Bock T, Wursthorn K, Manns MP, Wedemeyer H. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010;48:2022-9. [PMID: 20351206 DOI: 10.1128/JCM.00084-10] [Cited by in Crossref: 60] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
60 Lee H, Park W, Yang JH, You KS. Management of hepatitis B virus infection. Gastroenterol Nurs 2010;33:120-6; quiz 127-8. [PMID: 20389225 DOI: 10.1097/SGA.0b013e3181d72c59] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al-Qahtani A, Al-Ashgar HA, Al-Mdani AS, Al-Akwaa A, Almutharea S, Khan MQ, Alghamdi AS, Farah T, Al-Hamoudi W, Saadeh M, Abdo AA. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. J Viral Hepat 2011;18:e217-25. [PMID: 21692936 DOI: 10.1111/j.1365-2893.2011.01437.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
62 Sun J, Hou JL, Xie Q, Li XH, Zhang JM, Wang YM, Wang H, Lai JY, Chen SJ, Jia JD, Sheng JF, Chan HL, Wang JF, Li MK, Jiang M, Popescu M, Sung JJ. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther. 2011;34:424-431. [PMID: 21692822 DOI: 10.1111/j.1365-2036.2011.04750.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
63 Cho HJ, Kim SS, Ahn SJ, Bae CB, Kim HG, Kim YJ, Lee SK, Song GW, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, Cho SW, Cheong JY. Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B. Clin Biochem 2012;45:1564-7. [PMID: 22885475 DOI: 10.1016/j.clinbiochem.2012.07.107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
64 Jaffer OS, Lung PFC, Bosanac D, Shah A, Sidhu PS. Is ultrasound elastography of the liver ready to replace biopsy? A critical review of the current techniques. Ultrasound 2012;20:24-32. [DOI: 10.1258/ult.2011.011043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Kim BK, Kim do Y, Han KH, Park JY, Kim JK, Paik YH, Lee KS, Chon CY, Ahn SH. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol. 2011;106:1654-1652, 1730. [PMID: 21691339 DOI: 10.1038/ajg.2011.160] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
66 Li J, Qiu SJ, She WM, Wang FP, Gao H, Li L, Tu CT, Wang JY, Shen XZ, Jiang W. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS One. 2012;7:e39307. [PMID: 22745730 DOI: 10.1371/journal.pone.0039307] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 8.2] [Reference Citation Analysis]
67 Sun Z, Liu X, Jiang J, Huang H, Wang J, Wu D, Li L. Toward Biomarker Development in Large Clinical Cohorts: An Integrated High-Throughput 96-Well-Plate-Based Sample Preparation Workflow for Versatile Downstream Proteomic Analyses. Anal Chem 2016;88:8518-25. [PMID: 27471874 DOI: 10.1021/acs.analchem.6b01333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
68 Schilsky ML. Hepatitis B "360". Transplant Proc 2013;45:982-5. [PMID: 23622604 DOI: 10.1016/j.transproceed.2013.02.099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
69 Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, Shen CH, Luo Y, Xin TY, Wang SY. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis. 2009;10:321-327. [PMID: 19906113 DOI: 10.1111/j.1751-2980.2009.00403.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
70 Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol. 2011;29:3270-3277. [PMID: 21788556 DOI: 10.1200/jco.2011.35.1635] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
71 Aguado JM, Cruz JJ, Virizuela JA, Aguilar M, Carmona A, Cassinello J, Gudiol C, Jiménez Fonseca P, Lizasoain M, Marco F, Ruiz I, Ruiz M, Salavert M, Vicente D, Carratalà J. Management of Infection and Febrile Neutropenia in Patients with Solid Cancer. Enferm Infecc Microbiol Clin 2017;35:451-60. [PMID: 26279208 DOI: 10.1016/j.eimc.2015.06.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
72 Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Viganò M. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol. 2012;56:1239-1246. [PMID: 22326467 DOI: 10.1016/j.jhep.2011.12.032] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
73 Takkenberg RB, Zaaijer HL, Menting S, Weegink CJ, Terpstra V, Cornelissen M, Dijkgraaf MG, Jansen PL, Reesink HW, Beld MG. Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2010;22:952-60. [PMID: 20150816 DOI: 10.1097/MEG.0b013e3283376a63] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
74 Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat. 2010;17:601-610. [PMID: 20529201 DOI: 10.1111/j.1365-2893.2010.01326.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
75 Yang H, Hung H, Lee M, Liu J, Jen C, Su J, Wang L, Lu S, You S, Iloeje UH, Chen C. Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2012;10:527-534.e2. [DOI: 10.1016/j.cgh.2011.12.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
76 Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. J Acquir Immune Defic Syndr 2011;58:e96-9. [PMID: 22005002 DOI: 10.1097/QAI.0b013e3182303937] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
77 Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19:594-601. [PMID: 23447407 DOI: 10.1002/lt.23628] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
78 Boglione L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D'Avolio A. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res 2014;102:35-43. [PMID: 24316030 DOI: 10.1016/j.antiviral.2013.11.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
79 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
80 Giles ML, Visvanathan K, Lewin SR, Sasadeusz J. Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv. 2012;67:37-44. [PMID: 22278077 DOI: 10.1097/ogx.0b013e31823e464b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
81 Lee KS. [Clevudine therapy in patients with chronic hepatitis B]. Korean J Hepatol 2009;15:119-21. [PMID: 19581763 DOI: 10.3350/kjhep.2009.15.2.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Qiu Q, Li Y, Duan XW, Yang LK, Chen Y, Li H, Wang L, Duan ZP. Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China. PLoS One 2014;9:e109652. [PMID: 25329072 DOI: 10.1371/journal.pone.0109652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
83 Akgöllü E, Bilgin R, Akkız H, Ülger Y, Kaya BY, Karaoğullarından Ü, Arslan YK. Association between chronic hepatitis B virus infection and HLA-DP gene polymorphisms in the Turkish population. Virus Res 2017;232:6-12. [PMID: 28119119 DOI: 10.1016/j.virusres.2017.01.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
84 Thai KTD, Götz H, Slingerland BCGC, Klaasse J, Schutten M, GeurtsvanKessel CH. An analysis of the predictive value of the HIV Ag/Ab screening assay within the performance characteristics of the DiaSorin LIAISON XL for the detection of blood-borne viruses. J Clin Virol 2018;102:95-100. [PMID: 29547874 DOI: 10.1016/j.jcv.2018.02.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011;Oct 12; Epub ahead of print. [PMID: 21989925 DOI: 10.1007/s12072-011-9314-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
86 Duarte-rojo A, Feld JJ. Hepatitis B Biomarkers: Clinical Significance of the Old and the New. Curr Hepatitis Rep 2010;9:187-96. [DOI: 10.1007/s11901-010-0053-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Dakin H, Bentley A, Dusheiko G. Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B. Value in Health 2010;13:922-33. [DOI: 10.1111/j.1524-4733.2010.00782.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
88 Ntagirabiri R, Munezero B, Nahimana C, Ndabaneze E. [Hepatitis B virus genotypes and evolutionary markers in chronic HBsAG patients in Bujumbura]. Pan Afr Med J 2016;23:95. [PMID: 27222687 DOI: 10.11604/pamj.2016.23.95.8424] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Yamazhan T, Kurtaran B, Pullukçu H, Yüksel E, Özkaya D, Taşbakan MI, Sipahi OR, Durusoy R, Aksu HSZ. Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres. Journal of Chemotherapy 2013;26:339-41. [DOI: 10.1179/1973947813y.0000000152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Croagh CMN, Bell SJ, Locarnini S, Desmond PV. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing: HBV DNA in assessment of CHB. Internal Medicine Journal 2012;42:170-5. [DOI: 10.1111/j.1445-5994.2011.02435.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
91 Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 2014;7:259-68. [DOI: 10.1586/eri.09.6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
92 Benghalia K, Roussin-Bretagne S, Marque-Juillet S, Colardelle P, Chochon M, Harzic M, Doll J. [Hepatitis B reactivation with rituximab in an HIV-infected anti-HBs antibody carrier]. Med Mal Infect 2011;41:437-9. [PMID: 21700407 DOI: 10.1016/j.medmal.2011.05.008] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Chen C, Chang M. HEPATITIS B AND PREGNANCY, THE SCIENTIFIC BASIS FOR PERINATAL PREVENTION. Fet Matern Med Rev 2010;21:89-113. [DOI: 10.1017/s0965539510000021] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
94 Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol 2015; 21(43): 12421-12429 [PMID: 26604649 DOI: 10.3748/wjg.v21.i43.12421] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Thursz M, Cooke GS, Hall AJ. Hepatitis B treatment in resource poor settings: time for action. Trop Med Int Health. 2010;15:2-4. [PMID: 19843297 DOI: 10.1111/j.1365-3156.2009.02410.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
96 Nguyen T, Locarnini S. Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge? Nat Rev Gastroenterol Hepatol. 2009;6:565-567. [PMID: 19789570 DOI: 10.1038/nrgastro.2009.160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
97 Fateen AA, Shahin RY, Farres MN, Eldeeb MA, Amer HA. Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. Annals of Hepatology 2012;11:464-70. [DOI: 10.1016/s1665-2681(19)31459-0] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
98 Tong GD, Zhang X, Zhou DQ, Wei CS, He JS, Xiao CL, Liu XL, Zheng YJ, Chen SN, Tang HH. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L. Chin J Integr Med 2014;20:263-71. [PMID: 23529834 DOI: 10.1007/s11655-013-1320-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
99 Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. J Dig Dis. 2013;14:446-450. [PMID: 23615131 DOI: 10.1111/1751-2980.12065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
100 Wang J, Du LY, Zhu X, Chen EQ, Tang H. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Indian J Med Microbiol. 2015;33 Suppl:20-25. [PMID: 25657151 DOI: 10.4103/0255-0857.148827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat 2011;2011:524027. [PMID: 22114737 DOI: 10.1155/2011/524027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Shin SR, Yoo BC, Choi MS, Lee DH, Song SM, Lee JH, Koh KC, Paik SW. A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B. Hepatol Int. 2011;5:664-670. [PMID: 21484144 DOI: 10.1007/s12072-010-9238-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
103 Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB, McMahon BJ. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52:2192-2205. [PMID: 20890947 DOI: 10.1002/hep.23934] [Cited by in Crossref: 101] [Cited by in F6Publishing: 84] [Article Influence: 8.4] [Reference Citation Analysis]
104 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
105 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
106 Chotiyaputta W, Lok ASF. Endpoints of hepatitis B treatment: Endpoints of HBV treatment. Journal of Viral Hepatitis 2010;17:675-84. [DOI: 10.1111/j.1365-2893.2010.01369.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
107 Locarnini S, Bowden S. Drug Resistance in Antiviral Therapy. Clinics in Liver Disease 2010;14:439-59. [DOI: 10.1016/j.cld.2010.05.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
108 Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol. 2011;17:261-267. [PMID: 22310790 DOI: 10.3350/kjhep.2011.17.4.261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
109 Leonard AN, Love BL, Norris LB, Siddiqui SK, Wallam MN, Bennett CL. Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol 2016;95:27-33. [PMID: 26382277 DOI: 10.1007/s00277-015-2502-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
110 Alsunaid SR, Ashraf H, Soubani AO. Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. Transpl Infect Dis 2018;20:e12960. [PMID: 29975806 DOI: 10.1111/tid.12960] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Feng H, Yin J, Han YP, Zhou XY, Chen S, Yang L, Yan JR, Zhang GX. Sustained Changes of Treg and Th17 Cells During Interferon-α Therapy in Patients with Chronic Hepatitis B. Viral Immunol 2015;28:412-7. [PMID: 26266573 DOI: 10.1089/vim.2015.0024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
112 Brook G, Soriano V, Bergin C. European guideline for the management of hepatitis B and C virus infections, 2010. Int J STD AIDS 2010;21:669-78. [DOI: 10.1258/ijsa.2010.010234] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
113 Cross V, Larkins S. Management of chronic Hepatitis B infection in the remote primary health care setting: The search for a suitable guideline: MANAGING HEPATITIS B IN REMOTE SETTINGS. Australian Journal of Rural Health 2011;19:95-100. [DOI: 10.1111/j.1440-1584.2011.01190.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
114 Lee YB, Lee J, Kim YJ, Yoon J, Lee H. The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection: Therapeutic Vaccination in Chronic Hepatitis B. J Med Virol 2015;87:575-82. [DOI: 10.1002/jmv.24091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
115 Cheng Y, Guindon S, Rodrigo A, Lim SG. Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. J Hepatol. 2013;58:217-224. [PMID: 23023011 DOI: 10.1016/j.jhep.2012.09.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
116 Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract. 2011;65:866-870. [PMID: 21762311 DOI: 10.1111/j.1742-1241.2011.02719.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
117 Hansen BE, Rijckborst V, Ter Borg MJ, Janssen HL. HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. J Med Virol. 2011;83:1917-1923. [PMID: 21915866 DOI: 10.1002/jmv.22208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
118 Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443-451. [PMID: 21563196 DOI: 10.1002/hep.24406] [Cited by in Crossref: 125] [Cited by in F6Publishing: 120] [Article Influence: 11.4] [Reference Citation Analysis]
119 Gagey D, Ravetti S, Castro EF, Gualdesi MS, Briñon MC, Campos RH, Cavallaro LV. Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells. Int J Antimicrob Agents 2010;36:566-9. [PMID: 20947311 DOI: 10.1016/j.ijantimicag.2010.08.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
120 Kim DY, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013;7:329-34. [PMID: 23710315 DOI: 10.5009/gnl.2013.7.3.329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
121 Roche B, Roque-Afonso AM, Nevens F, Samuel D. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation. 2015;99:1321-1334. [PMID: 26038873 DOI: 10.1097/tp.0000000000000777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
122 Ridruejo E, Silva MO. Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Expert Opinion on Drug Safety 2012;11:357-60. [DOI: 10.1517/14740338.2012.672972] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
123 Rodriguez-Frías F, Tabernero D, Quer J, Esteban JI, Ortega I, Domingo E, Cubero M, Camós S, Ferrer-Costa C, Sánchez A, Jardí R, Schaper M, Homs M, Garcia-Cehic D, Guardia J, Esteban R, Buti M. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One 2012;7:e37874. [PMID: 22666402 DOI: 10.1371/journal.pone.0037874] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
124 Chien R, Liaw Y. Current treatment of chronic HBV infection: An Asian-Pacific perspective. Curr hepatitis rep 2009;8:154-60. [DOI: 10.1007/s11901-009-0022-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL;  Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092-2100. [PMID: 24002804 DOI: 10.1002/hep.26718] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 22.4] [Reference Citation Analysis]
126 Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235-1240. [PMID: 21703180 DOI: 10.1016/j.jhep.2011.03.030] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
127 Ooi M, Teoh NC. Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B-related complications? J Gastroenterol Hepatol 2012;27:1541-3. [PMID: 22994430 DOI: 10.1111/j.1440-1746.2012.07221.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Vallet-Pichard A, Pol S. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure]. Nephrol Ther 2015;11:507-20. [PMID: 26423779 DOI: 10.1016/j.nephro.2015.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Zhang ZQ, Wang GS, Kang KF, Wu GB, Wang P. Nomogram for hepatic steatosis: A simple and economical diagnostic tool for massive screening. Dig Liver Dis 2016;48:914-20. [PMID: 27246795 DOI: 10.1016/j.dld.2016.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
130 Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, Lee KF, Lai PB, Chan HL. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther. 2015;41:199-208. [PMID: 25413146 DOI: 10.1111/apt.13034] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
131 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
132 Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591-1599. [PMID: 22045673 DOI: 10.1002/hep.24555] [Cited by in Crossref: 145] [Cited by in F6Publishing: 132] [Article Influence: 14.5] [Reference Citation Analysis]
133 Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res 2015;45:1220-7. [PMID: 25627550 DOI: 10.1111/hepr.12496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
134 Sayan M, Akhan SC, Senturk O. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon 2011;11:835-42. [PMID: 22224083 DOI: 10.5812/kowsar.1735143X.775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
135 Pastor R, Habersetzer F, Fafi-Kremer S, Doffoël M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol 2009; 15(6): 753-755 [PMID: 19222103 DOI: 10.3748/wjg.15.753] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
136 Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF; APPROACH Working Group. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010;4:386-395. [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
137 Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56 Suppl 1:S112-S122. [PMID: 22300461 DOI: 10.1016/s0168-8278(12)60012-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
138 Devi U, Locarnini S. Hepatitis B antivirals and resistance. Current Opinion in Virology 2013;3:495-500. [DOI: 10.1016/j.coviro.2013.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
139 Bayat M, Taherpour AA, Elahi SM. Molecular interactions between PAMAM dendrimer and some medicines that suppress the growth of hepatitis virus (Adefovir, Entecavir, Telbivudine, Lamivudine, Tenofovir): a theoretical study. Int Nano Lett 2019;9:231-44. [DOI: 10.1007/s40089-019-0277-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol. 2010;25:892-898. [PMID: 20546442 DOI: 10.1111/j.1440-1746.2009.06161.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
141 Caliendo AM, Valsamakis A, Bremer JW, Ferreira-Gonzalez A, Granger S, Sabatini L, Tsongalis GJ, Wang YF, Yen-Lieberman B, Young S, Lurain NS. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. J Clin Microbiol 2011;49:2854-8. [PMID: 21697326 DOI: 10.1128/JCM.00471-11] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
142 Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300. [PMID: 21204745 DOI: 10.1517/14712598.2011.546340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
143 Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279. [PMID: 23390496 DOI: 10.1371/journal.pone.0054279] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
144 Toscanini F, De Leo P, Calcagno G, Malfatti F, Grasso A, Anselmo M. Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia. Case Reports Hepatol 2011;2011:258791. [PMID: 25954538 DOI: 10.1155/2011/258791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Kim MN, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Han KH. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int. 2014;34:1216-1223. [PMID: 24267737 DOI: 10.1111/liv.12377] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
146 Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
147 Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. J Virol. 2010;84:1026-1033. [PMID: 19889778 DOI: 10.1128/jvi.01796-09] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
148 Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, Guitard J, Izopet J, Alric L, Kamar N. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation. 2011;91:916-920. [PMID: 21325995 DOI: 10.1097/tp.0b013e3182100f59] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
149 Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA. Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients. J Viral Hepat 2016;23:170-9. [PMID: 26436722 DOI: 10.1111/jvh.12477] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
150 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
151 Hsu CW, Yeh CT. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology. 2011;54:101-108. [PMID: 21503942 DOI: 10.1002/hep.24363] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
152 Karahasanoğlu FB, Asan A, Sacar S, Turgut H. Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections. Balkan Med J. 2013;30:375-381. [PMID: 25207144 DOI: 10.5152/balkanmedj.2013.7547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
153 Reiser M. [Viral hepatitis B und C]. Med Klin (Munich) 2009;104:356-62. [PMID: 19444416 DOI: 10.1007/s00063-009-1074-y] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
154 Ha NB, Ha NB, Chaung KT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study. Dig Dis Sci 2014;59:168-73. [DOI: 10.1007/s10620-013-2940-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
155 Fink SA, Jacobson IM. Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2011;8:285-95. [DOI: 10.1038/nrgastro.2011.57] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
156 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
157 Xie HP, Yang HZ, Wu WK, Guan WB, Ke QS, Li YW, Dai M, Xiao GM, Zhang JS, Li YM. Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase. Chin J Integr Med 2014;20:94-100. [PMID: 24619234 DOI: 10.1007/s11655-013-1569-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
158 Lin LY, Wong VW, Zhou HJ, Chan HY, Gui HL, Guo SM, Wang H, Huang L, Bao SS, Xie Q. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol. 2010;82:1494-1500. [PMID: 20648602 DOI: 10.1002/jmv.21863] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
159 Albayrak A, Uyanik MH, Cerrah S, Altas S, Dursun H, Demir M, Uslu H. Is HMGB1 a New Indirect Marker for Revealing Fibrosis in Chronic Hepatitis and a New Therapeutic Target in Treatment? Viral Immunology 2010;23:633-8. [DOI: 10.1089/vim.2010.0080] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
160 Ruiz-Artacho P, Téllez-Molina MJ, Vergas-García J, Altali-Alhames K, Estrada-Pérez V, Fernández-Cruz-Pérez A. HIV/HBV coinfection: serological control and therapeutic strategies. Rev Clin Esp (Barc) 2013;213:285-90. [PMID: 23541287 DOI: 10.1016/j.rce.2013.01.013] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
161 Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect. 2014;142:270-286. [PMID: 23714072 DOI: 10.1017/s0950268813000940] [Cited by in Crossref: 124] [Cited by in F6Publishing: 70] [Article Influence: 13.8] [Reference Citation Analysis]
162 Gentile G, Foà R. Viral infections associated with the clinical use of monoclonal antibodies. Clinical Microbiology and Infection 2011;17:1769-75. [DOI: 10.1111/j.1469-0691.2011.03680.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
163 Papatheodoridis GV, Manolakopoulos S. EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol. 2009;51:226-227. [PMID: 19410321 DOI: 10.1016/j.jhep.2009.02.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
164 Josephus Jitta D, Wagenaar LJ, Mulder BJ, Guichelaar M, Bouman D, van Melle JP. Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. International Journal of Cardiology 2016;206:21-6. [DOI: 10.1016/j.ijcard.2015.12.033] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
165 Gwak G, Eo SJ, Shin SR, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. Hepatol Int 2013;7:106-10. [DOI: 10.1007/s12072-012-9368-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
166 Tan YLJ, Chen WN. MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2014; 20(20): 5973-5986 [PMID: 24876720 DOI: 10.3748/wjg.v20.i20.5973] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
167 Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant. 2012;26:E561-E569. [PMID: 23061767 DOI: 10.1111/ctr.12022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
168 El-hariri M, Abd El Megid AG, Taha Ali TF, Hassany M. Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. The Egyptian Journal of Radiology and Nuclear Medicine 2017;48:329-37. [DOI: 10.1016/j.ejrnm.2017.03.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
169 Kim YM, Jeong S, Kim J, Lee SH, Hwang JH, Park YS, Kim N, Lee JS, Kim HY, Lee DH. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy. Journal of Clinical Virology 2011;51:241-5. [DOI: 10.1016/j.jcv.2011.05.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
170 Ismail AM, Ramachandran J, Kannangai R, Abraham P. Antiviral efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B subjects from Indian subcontinent. Indian J Med Microbiol 2014;32:60-3. [PMID: 24399391 DOI: 10.4103/0255-0857.124312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Lee HM, Ahn J, Kim WR, Lim JK, Nguyen M, Pan CQ, Kim D, Mannalithara A, Te H, Trinh H, Chu D, Tran T, Woog J, Lok AS. A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. Dig Dis Sci 2019;64:358-66. [PMID: 30238203 DOI: 10.1007/s10620-018-5281-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
172 Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010;48:22-6. [PMID: 20233672 DOI: 10.1016/j.jcv.2010.02.014] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
173 Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2142-50. [PMID: 25072501 DOI: 10.1097/MIB.0000000000000126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
174 McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs. 2010;70:1857-1883. [PMID: 20836578 DOI: 10.2165/11204330-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
175 Cho Y, Song B. New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B. Korean J Gastroenterol 2011;57:144. [DOI: 10.4166/kjg.2011.57.3.144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
176 Rashed-Ul Islam SM, Jahan M, Tabassum S. Evaluation of a Rapid One-step Real-time PCR Method as a High-throughput Screening for Quantification of Hepatitis B Virus DNA in a Resource-limited Setting. Euroasian J Hepatogastroenterol 2015;5:11-5. [PMID: 29201678 DOI: 10.5005/jp-journals-10018-1121] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G. The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis. 2013;56:951-960. [PMID: 23223601 DOI: 10.1093/cid/cis1013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
178 Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis. 2009;1:e2009025. [PMID: 21415959 DOI: 10.4084/mjhid.2009.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
179 Ercin CN, Dogru T, Sertoglu E. Neutrophil-to-lymphocyte ratio as a predictor of fibrosis in inactive hepatitis B carriers. Eur J Gastroenterol Hepatol 2015;27:475-6. [PMID: 25874526 DOI: 10.1097/MEG.0000000000000311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
181 Wang L, Pan Y, Zhang K, Zhang R, Sun Y, Xie J, Li J. A 10-year human hepatitis B virus nucleic test external quality assessment in China: continual improvement. Clin Chim Acta 2013;425:139-47. [PMID: 23916788 DOI: 10.1016/j.cca.2013.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
182 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 2014; 20(24): 7635-7643 [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
183 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
184 Lai M, Liaw Y. Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease 2010;14:531-46. [DOI: 10.1016/j.cld.2010.05.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
185 Ibragimov EK, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Odintsov AV, Panevkina SV, Moiseev SV. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Ter Arkh 2019;91:40-7. [PMID: 31094170 DOI: 10.26442/ 00403660.2019.02.000073] [Reference Citation Analysis]
186 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
187 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 Kim BK, Ahn SH, Han K, Park JY, Han MS, Jo JH, Kim JK, Lee KS, Chon CY, Kim DY. Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion 2012;86:264-72. [DOI: 10.1159/000341507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
189 Fontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol. 2010;52:147-149. [PMID: 20006400 DOI: 10.1016/j.jhep.2009.10.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
190 Martinot-Peignoux M, Marcellin P. Virological and serological tools to optimize the management of patients with chronic hepatitis B. Liver Int 2016;36 Suppl 1:78-84. [PMID: 26725902 DOI: 10.1111/liv.12998] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
191 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
192 Ceccarelli L, Salpini R, Sarmati L, Svicher V, Bertoli A, Sordillo P, Ricciardi A, Perno CF, Andreoni M, Sarrecchia C. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65:180-183. [PMID: 22138369 DOI: 10.1016/j.jinf.2011.11.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
193 Sherman M. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment. J Hepatol. 2009;50:854-856. [PMID: 19303162 DOI: 10.1016/j.jhep.2009.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Venkatesh SK, Xu S, Tai D, Yu H, Wee A. Correlation of MR elastography with morphometric quantification of liver fibrosis (Fibro-C-Index) in chronic hepatitis B. Magn Reson Med. 2014;72:1123-1129. [PMID: 24166665 DOI: 10.1002/mrm.25002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
195 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
196 But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf. 2010;9:821-829. [PMID: 20662545 DOI: 10.1517/14740338.2010.507190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
197 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
198 Zhang X, Liu L, Xu W, Wang Y, Gao S, Chen S, DU Y. Intracellular levels of hepatitis B virus DNA and mutational patterns of the polymerase gene of hepatitis B virus in peripheral blood mononuclear cells of patients with lamivudine or telbivudine resistance. Exp Ther Med 2015;9:885-90. [PMID: 25667647 DOI: 10.3892/etm.2014.2156] [Reference Citation Analysis]
199 Cowan ML, Thomas HC, Foster GR. Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. Clin Med (Lond) 2011;11:184-9. [PMID: 21526708 DOI: 10.7861/clinmedicine.11-2-184] [Reference Citation Analysis]
200 Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012;26:939-49. [PMID: 22333748 DOI: 10.1097/QAD.0b013e328352224d] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
201 Nousbaum JB. [A 23-year-old asymptomatic HBsAg positive woman]. Gastroenterol Clin Biol 2009;33:F56-9. [PMID: 19762187 DOI: 10.1016/j.gcb.2009.07.029] [Reference Citation Analysis]
202 Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012;84:207-216. [PMID: 22170539 DOI: 10.1002/jmv.23182] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
203 Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91:1007-1012. [PMID: 22273839 DOI: 10.1007/s00277-012-1405-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
204 Brill JR. Sexually Transmitted Infections in Men. Primary Care: Clinics in Office Practice 2010;37:509-25. [DOI: 10.1016/j.pop.2010.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
205 Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, Guastafierro S, Coppola N. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013;41:225-9. [DOI: 10.1007/s15010-012-0305-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
206 Zhang N, Reijnders JGP, Perquin M, Hansen BE, Janssen HLA. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Journal of Viral Hepatitis 2011;18. [DOI: 10.1111/j.1365-2893.2011.01448.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
207 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
208 Yan LB, Chen EQ, Bai L, Du LY, Chen LL, Liao J, He M, Tang H. Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load. Clin Res Hepatol Gastroenterol 2015;39:366-72. [PMID: 25468548 DOI: 10.1016/j.clinre.2014.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
209 Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 2011; 17(18): 2273-2282 [PMID: 21633593 DOI: 10.3748/wjg.v17.i18.2273] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
210 Maklad S, Doss W, El Din SS, Hassan K, Zeid AA. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. Arab J Gastroenterol. 2014;15:1-5. [PMID: 24630505 DOI: 10.1016/j.ajg.2014.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
211 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
212 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635-7643. [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
213 Yang F, Zhu HL, He C, Li JJ, Xiang B, Cui X, Huang J, Ji J, Ma HB, Liu T. Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. Indian J Hematol Blood Transfus 2014;30:97-104. [PMID: 24839363 DOI: 10.1007/s12288-012-0195-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
214 Sayan M, Akhan SC. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B. Int J Infect Dis. 2011;15:e722-e726. [PMID: 21784687 DOI: 10.1016/j.ijid.2011.05.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
215 Ruan P, Xu SY, Zhou BP, Huang J, Gong ZJ. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study. J Int Med Res 2013;41:1732-9. [PMID: 23908397 DOI: 10.1177/0300060513487643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
216 Li W, Huang L, Guo H, Wei X, Liang Z. Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. J Clin Virol. 2014;61:199-203. [PMID: 25128391 DOI: 10.1016/j.jcv.2014.07.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
217 Tramuto F, Maida CM, Colomba GM, Di Carlo P, Mazzola G, Li Vecchi V, Affronti M, Montalto G, Vitale F. Occult hepatitis B infection in the immigrant population of Sicily, Italy. J Immigr Minor Health 2013;15:725-31. [PMID: 22875279 DOI: 10.1007/s10903-012-9699-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
218 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20:e3-10. [PMID: 23490387 DOI: 10.1111/jvh.12010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
219 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.0] [Reference Citation Analysis]
220 Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010;52:594-604. [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033] [Cited by in Crossref: 259] [Cited by in F6Publishing: 264] [Article Influence: 21.6] [Reference Citation Analysis]
221 Pan Q, Yu Y, Tang Z, Xi M, Jiang H, Xun Y, Liu X, Liu H, Hu J, Zang G. Increased levels of IL-21 responses are associated with the severity of liver injury in patients with chronic active hepatitis B. J Viral Hepat. 2014;21:e78-e88. [PMID: 24611989 DOI: 10.1111/jvh.12242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
222 Zhang F, Wang G. A review of non-nucleoside anti-hepatitis B virus agents. Eur J Med Chem 2014;75:267-81. [PMID: 24549242 DOI: 10.1016/j.ejmech.2014.01.046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
223 Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol. 2012;47:1048-1055. [PMID: 22726105 DOI: 10.3109/00365521.2012.694902] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
224 Park JS, Gayam V, Pan CQ. Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020;52:944-954. [PMID: 32743822 DOI: 10.1111/apt.15999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Yan CH, Zhao CY, Ding H, Peng YQ, Jin PY, Yan L, Zhuang H, Li T. Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. Antiviral Res. 2012;96:108-114. [PMID: 22960603 DOI: 10.1016/j.antiviral.2012.08.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
226 Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011;26 Suppl 1:131-137. [PMID: 21199524 DOI: 10.1111/j.1440-1746.2010.06544.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
227 Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013;17:399-412. [PMID: 23905812 DOI: 10.1016/j.cld.2013.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
228 Sherman M, Lee SS. Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol 2011;25:538-41. [PMID: 22059156 DOI: 10.1155/2011/864046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
229 Wong TC, Fung JY, Lo CM. Prevention of recurrent hepatitis B infection after liver transplantation. Hepatobiliary & Pancreatic Diseases International 2013;12:465-72. [DOI: 10.1016/s1499-3872(13)60074-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
230 Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C. Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol. 2010;162:1408-1410. [PMID: 20184582 DOI: 10.1111/j.1365-2133.2010.09714.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
231 Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS. HBV DNA loss within 24 weeks predicts late viral breakthrough in chronic hepatitis B. Korean J Gastroenterol 2011;58:25-30. [PMID: 21778800 DOI: 10.4166/kjg.2011.58.1.25] [Reference Citation Analysis]
232 Requena T, Martín MT, Desongles T, Castillo I, Lorente L, Yébenes M; and the EUPTHEA Group. Prescription pattern for antivirals in the treatment of chronic hepatitis B: the EUPTHEA Study. Eur J Hosp Pharm 2013;20:174-9. [DOI: 10.1136/ejhpharm-2012-000206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat 2011;18:e29-39. [PMID: 21392168 DOI: 10.1111/j.1365-2893.2010.01360.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
234 Martín-mateos RM, Moreira Vicente VF, Téllez-villajos L, García-sánchez C, Maroto-castellanos MT, García-alonso FJ, Mateos-lindemann ML, Albillos A. Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica. Gastroenterología y Hepatología 2014;37:280-8. [DOI: 10.1016/j.gastrohep.2013.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
235 Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103. [PMID: 20180785 DOI: 10.1111/j.1365-2036.2010.04276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 7.3] [Reference Citation Analysis]
236 Wu C, Zhang H, Qian Y, Wang L, Gu X, Dai Z. Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. J Clin Pharm Ther. 2013;38:321-326. [PMID: 23590583 DOI: 10.1111/jcpt.12050] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
237 Zeng DW, Zhu YY, Huang Q, Zhang JM, Wu YL, Dong J, Jiang JJ, Liu YR. Hepatitis B surface antigen in late hepatitis B infection. J Med Virol. 2015;87:380-387. [PMID: 25604455 DOI: 10.1002/jmv.24078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
238 Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287-98. [PMID: 21481584 DOI: 10.1016/j.ejca.2011.02.014] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 9.7] [Reference Citation Analysis]
239 Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat. 2010;17:624-630. [PMID: 20487257 DOI: 10.1111/j.1365-2893.2010.01318.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
240 Lee M, Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol. 2011;54:6-8. [PMID: 20951458 DOI: 10.1016/j.jhep.2010.09.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
241 Ballanti E, Conigliaro P, Chimenti MS, Kroegler B, Di Muzio G, Guarino MD, Triggianese P, Gigliucci G, Novelli L, Barbato C. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014;75 Suppl 1:S42-S45. [PMID: 25381975 DOI: 10.1002/ddr.21193] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
242 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
243 Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology 2010;51:1107-9. [DOI: 10.1002/hep.23496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
244 Haider M, Flocco G, Lopez R, Carey W. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open 2020;10:e043672. [PMID: 33323450 DOI: 10.1136/bmjopen-2020-043672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy: Prevention of HBV reactivation. Hepatology Research 2012;42:627-36. [DOI: 10.1111/j.1872-034x.2012.00998.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
246 Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D, Loustau-ratti V, Morlat P, Goderel I, Sene D, Rosenthal E, Carrat F, Cacoub P. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. Journal of Hepatology 2010;53:1006-12. [DOI: 10.1016/j.jhep.2010.04.041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
247 Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8. [PMID: 22343167 DOI: 10.1016/j.jhep.2012.01.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
248 Thongthae N, Payungporn S, Poovorawan Y, T-Thienprasert NP. A rational study for identification of highly effective siRNAs against hepatitis B virus. Exp Mol Pathol. 2014;97:120-127. [PMID: 24953337 DOI: 10.1016/j.yexmp.2014.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
249 Ren S, Yu H, Zhang H, Liu Y, Huang Y, Ma L, Wei L, Wu H, Chen X. Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection. Antiviral Res 2011;89:232-7. [PMID: 21277331 DOI: 10.1016/j.antiviral.2011.01.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
250 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
251 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
252 Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther. 2011;33:501-513. [PMID: 21198707 DOI: 10.1111/j.1365-2036.2010.04555.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
253 Dandri M, Lütgehetmann M, Petersen J. Experimental models and therapeutic approaches for HBV.Semin Immunopathol. 2013;35:7-21. [PMID: 22898798 DOI: 10.1007/s00281-012-0335-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
254 Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408-414. [PMID: 21742839 DOI: 10.1093/infdis/jir283] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 7.1] [Reference Citation Analysis]
255 Zoutendijk R, Sonneveld MJ, Reijnders JG, van Vuuren AJ, Biesta P, Hansen BE, Boonstra A, Janssen HL. Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues. J Viral Hepat 2013;20:322-7. [PMID: 23565614 DOI: 10.1111/jvh.12033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
256 Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database Syst Rev 2011;:CD008960. [PMID: 21491412 DOI: 10.1002/14651858.CD008960.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
257 Hilgendorf I, Loebermann M, Borchert K, Junghanss C, Freund M, Schmitt M. Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. Bone Marrow Transplant 2011;46:1274-5. [PMID: 21151183 DOI: 10.1038/bmt.2010.290] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
258 Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006-1011. [PMID: 22245886 DOI: 10.1016/j.jhep.2011.12.007] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 12.3] [Reference Citation Analysis]
259 Chan HL, Thompson A, Martinot-peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao J, Jia J, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology 2011;55:1121-31. [DOI: 10.1016/j.jhep.2011.06.006] [Cited by in Crossref: 206] [Cited by in F6Publishing: 200] [Article Influence: 18.7] [Reference Citation Analysis]
260 Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, Thursz M. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 2016;4:e568-78. [PMID: 27443782 DOI: 10.1016/S2214-109X(16)30101-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 15.3] [Reference Citation Analysis]
261 Montineri A, Nigro L, La Rosa R, Iacobello C, Larocca L, Cappello E, Fiumara PF, Di Raimondo F, Fatuzzo F. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. J Clin Virol 2011;52:284-7. [PMID: 21906994 DOI: 10.1016/j.jcv.2011.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
262 Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703-711. [PMID: 25412906 DOI: 10.1002/hep.27609] [Cited by in Crossref: 134] [Cited by in F6Publishing: 115] [Article Influence: 19.1] [Reference Citation Analysis]
263 Perry CM, Simpson D. Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs. 2009;69:2245-2256. [PMID: 19852527 DOI: 10.2165/10482940-000000000-00000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
264 Liu W, Hu Y, Yang Y, Hu T, Wang X. Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies. Arch Virol 2015;160:191-8. [PMID: 25323529 DOI: 10.1007/s00705-014-2253-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Broquetas T, Garcia-Retortillo M, Hernandez JJ, Puigvehí M, Cañete N, Coll S, Cabrero B, Giménez MD, Solà R, Carrión JA. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. PLoS One 2017;12:e0188303. [PMID: 29190670 DOI: 10.1371/journal.pone.0188303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
266 Fiorini E, Cipriano V, De Molo C, Righi S, Ainora ME, Arcelli A, Bertusi C, Montanari M, Bianchi G, Serra C. Real-time elastography as a noninvasive technique for quantification of fibrosis in patients with chronic viral liver disease: Preliminary findings. J Ultrasound 2012;15:220-5. [PMID: 23730385 DOI: 10.1016/j.jus.2012.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
267 Tanwar S, Dusheiko G. Is There Any Value to Hepatitis B Virus Genotype Analysis? Curr Gastroenterol Rep 2012;14:37-46. [DOI: 10.1007/s11894-011-0233-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
268 Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011;9:891-899. [PMID: 21973301 DOI: 10.1586/eri.11.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
269 Jin YJ, Shim JH, Chung YH, Kim JA, Choi JG, Park WH, Lee D, Kim SE, Lee YS, Kim SH, Yang SH. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. Digestion 2011;84 Suppl 1:35-42. [PMID: 22156484 DOI: 10.1159/000333783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
270 Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29] [Reference Citation Analysis]
271 García-Alonso FJ, Martín-Mateos RM, Moreira Vicente V. [Pharmacological treatment of acute hepatitis B]. Med Clin (Barc) 2012;138:633-7. [PMID: 22118973 DOI: 10.1016/j.medcli.2011.09.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
272 Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323-1331. [PMID: 21050234 DOI: 10.1111/j.1365-2036.2010.04474.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
273 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
274 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 292] [Article Influence: 55.7] [Reference Citation Analysis]
275 Cui F, Meng J, Luo P, Chen P. IFN- alpha blocks IL-17 production by peripheral blood mononuclear cells in patients with chronic active hepatitis B Infection. BMC Infect Dis 2014;14:55. [PMID: 24484458 DOI: 10.1186/1471-2334-14-55] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
276 Li X, Xing Y, Lin Q, Dong M, Wan X, Wu X. The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol 2012;9:350-350. [DOI: 10.1038/nrclinonc.2012.1-c1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
277 Deutsch M, Papadopoulos N, Manolakopoulos S, Hatziyanni E, Vassilopoulos D. Fatal hepatitis B virus reactivation due to a lamivudine mutant despite undetectable initial viral load. Eur J Gastroenterol Hepatol 2011;23:109. [PMID: 21139472 DOI: 10.1097/MEG.0b013e32834124c4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
278 Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13:934-945. [PMID: 20825624 DOI: 10.1111/j.1524-4733.2010.00777.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
279 Cristina SJL, Marta CM, Mercedes GS, Almudena PM, Álvaro HM, Luis VSJ, Tesifón PC. Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases. Clin Mol Hepatol 2018;24:384-91. [PMID: 29969885 DOI: 10.3350/cmh.2018.0004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
280 Cao Y, He K, Cheng M, Si HY, Zhang HL, Song W, Li AL, Hu CJ, Wang N. Two classifiers based on serum peptide pattern for prediction of HBV-induced liver cirrhosis using MALDI-TOF MS. Biomed Res Int 2013;2013:814876. [PMID: 23509784 DOI: 10.1155/2013/814876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
281 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84-S101. [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021] [Cited by in Crossref: 330] [Cited by in F6Publishing: 335] [Article Influence: 66.0] [Reference Citation Analysis]
282 Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42): 6106-6113 [PMID: 23155339 DOI: 10.3748/wjg.v18.i42.6106] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
283 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
284 Wan MB, Weng XH. Expert recommendations on the application of interferon for chronic hepatitis B. J Dig Dis. 2013;14:626-637. [PMID: 23981279 DOI: 10.1111/1751-2980.12096] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
285 Okonkwo UC, Onyekwere CA. Challenges in the management of chronic HBV infection in West Africa: The clinician's perspective. Trop Doct 2016;46:16-20. [PMID: 25505192 DOI: 10.1177/0049475514561822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
286 Fernández I, Loinaz C, Hernández O, Abradelo M, Manrique A, Calvo J, Manzano M, García A, Cambra F, Castellano G, Jiménez C. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis 2015;17:695-701. [PMID: 26257166 DOI: 10.1111/tid.12434] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
287 Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol 2015; 7(10): 1421-1426 [PMID: 26052387 DOI: 10.4254/wjh.v7.i10.1421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
288 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
289 Idilman R, Bozkus Y, Seval G, Mizrak D, Cinar K, Ustun Y, Bektas M, Arat M, Akbulut H, Doganay B, Ozden A. Lymphoproliferative disorders in individuals with chronic hepatitis B and C in the Turkish population. J Med Virol 2011;83:974-80. [PMID: 21503909 DOI: 10.1002/jmv.21747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
290 Ji D, Liu Y, Li L, Xu Z, Si LL, Dai JZ, Li X, Wang L, Yao Z, Xin SJ. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol. 2012;54:66-72. [PMID: 22398037 DOI: 10.1016/j.jcv.2012.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
291 Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009;33:1082-1093. [PMID: 19896313 DOI: 10.1016/j.gcb.2009.03.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
292 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
293 Dai J, Chen EQ, Bai L, Gong DY, Zhou QL, Cheng X, Huang FJ, Tang H. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model. Virol J 2012;9:280. [PMID: 23171829 DOI: 10.1186/1743-422X-9-280] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
294 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
295 Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351 [PMID: 26413224 DOI: 10.4254/wjh.v7.i21.2344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
296 Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte AD, Flisiak R, Lundgren J; on behalf of EuroSIDA. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. Journal of Antimicrobial Chemotherapy 2010;65:548-55. [DOI: 10.1093/jac/dkp479] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
297 Sayan M, Dogan C. Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B. Annals of Hepatology 2012;11:849-54. [DOI: 10.1016/s1665-2681(19)31409-7] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
298 Manolakopoulos S, Striki A, Deutsch M, Mela M, Ketikoglou I, Tzourmakliotis D, Manesis EK, Papatheodoridis GV. Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int. 2011;31:1525-1532. [PMID: 22093327 DOI: 10.1111/j.1478-3231.2011.02616.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
299 Eser Karlidag G, Karlidag T, Demirdag K, Keles E. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011;38:312-8. [PMID: 21216118 DOI: 10.1016/j.anl.2010.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
300 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med 2019;8:5097-107. [PMID: 31313476 DOI: 10.1002/cam4.2380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
301 Lai CL, Yuen MF. The saga of entecavir. Hepatol Int 2009;3:421-4. [PMID: 19669247 DOI: 10.1007/s12072-009-9138-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
302 Wai-sun Wong V, Lik-yuen Chan H. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology 2012;11:284-93. [DOI: 10.1016/s1665-2681(19)30922-6] [Cited by in Crossref: 14] [Article Influence: 1.4] [Reference Citation Analysis]
303 Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011;35:813-8. [PMID: 21821479 DOI: 10.1016/j.clinre.2011.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
304 Chakravarty R. Role of molecular diagnostics in the management of viral hepatitis B. Expert Opin Med Diagn 2012;6:395-406. [PMID: 23480805 DOI: 10.1517/17530059.2012.690391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
305 Liu F, Yu DM, Huang SY, Yu JL, Zhang DH, Gong QM, Zhang XX. Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection. J Clin Microbiol 2014;52:1556-65. [PMID: 24574300 DOI: 10.1128/JCM.03338-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
306 l'Association Française pour l'Etude du Foie. [Hepatitis B: the French point of view on EASL guidelines]. Gastroenterol Clin Biol 2009;33:535-8. [PMID: 19505784 DOI: 10.1016/j.gcb.2009.05.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
307 Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17:1176-1190. [PMID: 21656655 DOI: 10.1002/lt.22354] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 8.3] [Reference Citation Analysis]
308 Maratea D, Fadda V, Trippoli S, Messori A. Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir. Aliment Pharmacol Ther 2013;37:584-5. [PMID: 23369168 DOI: 10.1111/apt.12212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
309 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
310 Chen L, Wang X, Zhang Q, Gong J, Shen S, Yin W, Hu H. Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. Gastroenterol Res Pract. 2016;2016:7214020. [PMID: 26880896 DOI: 10.1155/2016/7214020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
311 Ruggeri M, Basile M, Coretti S, Drago C, Cicchetti A. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Appl Health Econ Health Policy 2017;15:479-90. [DOI: 10.1007/s40258-017-0311-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
312 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
313 Wang S, Han Q, Zhang G, Zhang N, Li Z, Chen J, Lv Y, Li N, Xing F, Tian N, Zhu Q, Liu Z. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. Int Immunopharmacol 2011;11:406-11. [PMID: 21182997 DOI: 10.1016/j.intimp.2010.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
314 Zhong YW, Di FL, Liu C, Zhang XC, Bi JF, Li YL, Wu SQ, Dong H, Liu LM, He J, Shi YM, Zhang HF, Zhang M. Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection. Clin Microbiol Infect 2016;22:379.e1-8. [PMID: 26577140 DOI: 10.1016/j.cmi.2015.10.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
315 Doganay L, Tuncer I, Katrinli S, Enc FY, Ozturk O, Colak Y, Ulasoglu C, Dinler G. The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs. Clin Res Hepatol Gastroenterol. 2013;37:359-364. [PMID: 23273495 DOI: 10.1016/j.clinre.2012.10.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
316 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
317 Emara MH, Radwan MI. Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient. Virol J 2011;8:518. [PMID: 22078891 DOI: 10.1186/1743-422X-8-518] [Reference Citation Analysis]
318 Yang J, Guo R, Yan D, Lu H, Zhang H, Ye P, Jin L, Diao H, Li L. Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment. Front Cell Infect Microbiol 2020;10:335. [PMID: 32793509 DOI: 10.3389/fcimb.2020.00335] [Reference Citation Analysis]
319 Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, Fu SY, Wu MC. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257:490-505. [PMID: 22868358 DOI: 10.1097/sla.0b013e318262b218] [Cited by in Crossref: 70] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
320 Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-1257. [PMID: 20830787 DOI: 10.1002/hep.23844] [Cited by in Crossref: 207] [Cited by in F6Publishing: 190] [Article Influence: 17.3] [Reference Citation Analysis]
321 Wang JY, Mao RC, Zhang YM, Zhang YJ, Liu HY, Qin YL, Lu MJ, Zhang JM. Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. J Viral Hepat. 2015;22:128-136. [PMID: 25131617 DOI: 10.1111/jvh.12284] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
322 Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. BMC Gastroenterol 2012;12:178. [PMID: 23234302 DOI: 10.1186/1471-230X-12-178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
323 Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
324 Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. Journal of Gastroenterology and Hepatology 2010;25:657-63. [DOI: 10.1111/j.1440-1746.2009.06167.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 7.6] [Reference Citation Analysis]
325 Ridruejo E, Adrover R, Alonso C, Mandó OG, Silva MO. Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation. Dial Transplant 2010;39:397-400. [DOI: 10.1002/dat.20485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
326 Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34 Suppl 1:97-107. [PMID: 24373085 DOI: 10.1111/liv.12403] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 8.5] [Reference Citation Analysis]
327 Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. Journal of Hepatology 2012;57:885-96. [DOI: 10.1016/j.jhep.2012.03.036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
328 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
329 Moucari R, Boyer N, Ripault M, Castelnau C, Mackiewicz V, Dauvergne A, Valla D, Vidaud M, Chanoine MN, Marcellin P. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients: Sequential therapy for HBeAg (−) patients. Journal of Viral Hepatitis 2011;18:580-6. [DOI: 10.1111/j.1365-2893.2010.01332.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
330 Wang CC, Tseng TC, Wang PC, Lin HH, Kao JH. Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. J Formos Med Assoc. 2013;Aug 1; Epub ahead of print. [PMID: 23911291 DOI: 10.1016/j.jfma.2013.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
331 Yu F, Yang J, Ouyang J, Zheng Y, Chen B, Li G, Lu Z, Dong P, Zheng J. Serum microRNA-210 levels in different groups of chronic hepatitis B patients. Clinica Chimica Acta 2015;450:203-9. [DOI: 10.1016/j.cca.2015.08.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
332 Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 2013;87:12-27. [PMID: 23313021 DOI: 10.1016/j.critrevonc.2012.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
333 Chan HL, Wong VW. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 540-63. [DOI: 10.1016/b978-1-4377-0881-3.00030-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
334 Ng CJ, Low WY, Wong LP, Sudin MR, Mohamed R. Uncovering the experiences and needs of patients with chronic hepatitis B infection at diagnosis: a qualitative study. Asia Pac J Public Health 2013;25:32-40. [PMID: 21807630 DOI: 10.1177/1010539511413258] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
335 Tu HAT, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the Northern Netherlands between 2000 and 2006. Clinical Therapeutics 2010;32:133-44. [DOI: 10.1016/j.clinthera.2010.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
336 Chevaliez S, Bouvier-Alias M, Laperche S, Hézode C, Pawlotsky JM. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol. 2010;48:3641-3647. [PMID: 20720031 DOI: 10.1128/jcm.01306-10] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
337 Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011;3:37-46. [PMID: 21935331 DOI: 10.2147/CEOR.S16655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
338 Kalyoncu U, Emmungil H, Onat AM, Yılmaz S, Kaşifoglu T, Akar S, İnanç N, Yıldız F, Küçükşahin O, Karadağ Ö, Mercan R, Bes C, Yazısız V, Yılmazer B, Özmen M, Erten Ş, Şenel S, Yazıcı A, Taşçılar K, Kalfa M, Kiraz S, Kısacık B, Pehlivan Y, Kılıç L, Şimşek İ, Çefle A, Akkoç N, Direskeneli H, Erken E, Turgay M, Öztürk MA, Soy M, Aksu K, Dinç A, Ertenli İ. Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). Eur J Rheumatol 2015;2:149-54. [PMID: 27708953 DOI: 10.5152/eurjrheum.2015.0111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
339 Sha WH, Zeng XH, Min L. The correlation between NK cell and liver function in patients with primary hepatocellular carcinoma. Gut Liver 2014;8:298-305. [PMID: 24827627 DOI: 10.5009/gnl.2014.8.3.298] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
340 Baqai SF, Proudfoot J, Yi DH, Mangahas M, Gish RG. High rate of core promoter and precore mutations in patients with chronic hepatitis B. Hepatol Int. 2015;9:209-217. [PMID: 25788186 DOI: 10.1007/s12072-014-9598-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
341 Castéra L, Bernard PH, Le Bail B, Foucher J, Trimoulet P, Merrouche W, Couzigou P, de Lédinghen V. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011;33:455-465. [PMID: 21235598 DOI: 10.1111/j.1365-2036.2010.04547.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
342 Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765-2772. [PMID: 23775967 DOI: 10.1200/jco.2012.48.5938] [Cited by in Crossref: 221] [Cited by in F6Publishing: 91] [Article Influence: 24.6] [Reference Citation Analysis]
343 Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13:245-54. [PMID: 22242973 DOI: 10.1517/14656566.2012.649727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
344 Tian Z, Wang M, Yao N, Yang S, Liu J, Yang Y, Chen T, Zhao Y, He Y. Expression of autophagy-modulating genes in peripheral blood mononuclear cells from familial clustering patients with chronic hepatitis B virus infection. Arch Virol 2019;164:2005-13. [PMID: 31102052 DOI: 10.1007/s00705-019-04248-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
345 Sonneveld MJ, Rijckborst V, Zwang L, Zeuzem S, Jenny Heathcote E, Simon K, Zoutendijk R, Akarca US, Pas SD, Hansen BE, Janssen HL. Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. Antiviral Res. 2013;97:312-317. [PMID: 23274785 DOI: 10.1016/j.antiviral.2012.12.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
346 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
347 Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47:1022-1029. [PMID: 22370817 DOI: 10.1007/s00535-012-0561-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
348 Delfino CM, Eirin ME, Berini C, Malan R, Gentile E, Castillo A, Pedrozo W, Krupp R, Blejer J, Oubiña JR, Mathet VL, Biglione MM. HDAg-L variants in covert hepatitis D and HBV occult infection among Amerindians of Argentina: new insights. Journal of Clinical Virology 2012;54:223-8. [DOI: 10.1016/j.jcv.2012.04.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
349 Désiré N, Sanchis T, Ben Moussa F, Stitou H, Katlama C, Thibault V. [Development and validation of a specific method for relative HBV-genotype G (G-HBV) quantification in the context of co-infection with other genotypes]. Pathol Biol (Paris). 2011;59:e13-e19. [PMID: 20822865 DOI: 10.1016/j.patbio.2010.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
350 Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One. 2012;7:e47648. [PMID: 23112829 DOI: 10.1371/journal.pone.0047648] [Cited by in Crossref: 175] [Cited by in F6Publishing: 169] [Article Influence: 17.5] [Reference Citation Analysis]
351 Kim JH, Kwon SY, Lee YS, Lee JH, Lee Y, Lee CH. Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2012;10:291-6. [DOI: 10.1016/j.cgh.2011.09.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
352 Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35:1326-1335. [PMID: 22506552 DOI: 10.1111/j.1365-2036.2012.05098.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
353 Miailhes P, Pradat P, Chevallier M, Lacombe K, Bailly F, Cotte L, Trabaud MA, Boibieux A, Bottero J, Trepo C. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat. 2011;18:61-69. [PMID: 20196798 DOI: 10.1111/j.1365-2893.2010.01275.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
354 Dusheiko G. Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis? Lancet. 2012;379:2019-2021. [PMID: 22549045 DOI: 10.1016/s0140-6736(11)61182-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
355 Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711-734. [PMID: 21950502 DOI: 10.1111/j.1365-2133.2011.10575.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 7.6] [Reference Citation Analysis]
356 Lu JJ, Chen EQ, Yang JH, Zhou TY, Liu L, Tang H. A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients. Virol J. 2012;9:10. [PMID: 22233973 DOI: 10.1186/1743-422x-9-10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
357 Brook G, Bhagani S, Kulasegaram R, Torkington A, Mutimer D, Hodges E, Hesketh L, Farnworth S, Sullivan V, Gore C, Devitt E, Sullivan AK; Clinical Effectiveness Group British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015. Int J STD AIDS 2016;27:501-25. [PMID: 26745988 DOI: 10.1177/0956462415624250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
358 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
359 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
360 Sacco R. Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med 2012;4:39-47. [PMID: 24696620 DOI: 10.2147/HMER.S16136] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
361 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
362 Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther 2014;3:191-202. [PMID: 25228496 DOI: 10.1007/s40121-014-0039-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
363 Montineri A, Nigro L, Chiarenza A, Larocca L, La Rosa R, Iacobello C, Di Raimondo F, Fatuzzo F. Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 2010;51:554-7. [DOI: 10.3109/10428190903553961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 McMahon BJ, Bulkow L, Simons B, Zhang Y, Negus S, Homan C, Spradling P, Teshale E, Lau D, Snowball M. Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen-Negative Persons With Hepatitis B. Clin Gastroenterol Hepatol. 2014;12:701-706.e3. [PMID: 24035774 DOI: 10.1016/j.cgh.2013.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
365 Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009;5:789-98. [PMID: 19851526 DOI: 10.2147/tcrm.s5318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
366 Xiao CX, Yang XN, Huang QW, Zhang YQ, Lin BY, Liu JJ, Liu YP, Jazag A, Guleng B, Ren JL. ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells. Cancer Lett 2013;330:67-73. [PMID: 23178449 DOI: 10.1016/j.canlet.2012.11.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
367 Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol. 2013;28:46-50. [PMID: 22989322 DOI: 10.1111/j.1440-1746.2012.07269.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
368 Leung C, Tsoi E, Burns G, Sievert W. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 2011;16:579-84. [PMID: 21464465 DOI: 10.1634/theoncologist.2010-0182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
369 Elewa U, Sandri AM, Kim WR, Fervenza FC. Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract 2011;119:c41-9; discussion c49. [PMID: 21677438 DOI: 10.1159/000324652] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
370 Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol 2010; 16(32): 4095-4099 [PMID: 20731026 DOI: 10.3748/wjg.v16.i32.4095] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
371 Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067. [PMID: 21188195 DOI: 10.1155/2010/182067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
372 Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 8.3] [Reference Citation Analysis]
373 Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611-1620. [PMID: 20931556 DOI: 10.1002/hep.23905] [Cited by in Crossref: 153] [Cited by in F6Publishing: 149] [Article Influence: 12.8] [Reference Citation Analysis]
374 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
375 Maklad S, Esmat G, Doss W, Abou-Zeid A, El-Din SS. Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience. Arab J Gastroenterol 2013;14:73-7. [PMID: 23820505 DOI: 10.1016/j.ajg.2013.04.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
376 Chatzidaki V, Kouroumalis E, Galanakis E. Hepatitis B virus acquisition and pathogenesis in childhood: host genetic determinants. J Pediatr Gastroenterol Nutr. 2011;52:3-8. [PMID: 21119536 DOI: 10.1097/mpg.0b013e3181fb0cb9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
377 Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732-743. [PMID: 22967105 DOI: 10.1111/j.1365-2893.2012.01600.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
378 Wursthorn K, Zacher BJ, Jaroszewicz J, Darnedde M, Manns M, Wedemeyer H. Development of a protocol for the quantitative determination of HBeAg using the Elecsys ® HBeAg immunoassay. Journal of Viral Hepatitis 2011;18. [DOI: 10.1111/j.1365-2893.2010.01419.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
379 Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol. 2009;50:644-647. [PMID: 19231017 DOI: 10.1016/j.jhep.2009.01.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
380 Sayan M, Akhan SC, Meric M. Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat 2010;17:23-7. [PMID: 19566788 DOI: 10.1111/j.1365-2893.2009.01149.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
381 Hadziyannis E, Vassilopoulos D, Hadziyannis SJ. Quantitative HBsAg titer as predictor of response to therapy. Curr hepatitis rep 2009;8:169-72. [DOI: 10.1007/s11901-009-0024-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
382 van de Putte DF, Blom R, van Soest H, Mundt M, Verveer C, Arends J, de Knegt RE, Mauser-bunschoten E, van Erpecum K. Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice. Annals of Hepatology 2011;10:469-76. [DOI: 10.1016/s1665-2681(19)31514-5] [Cited by in Crossref: 14] [Article Influence: 1.3] [Reference Citation Analysis]
383 Liu H, Wang X, Wan G, Yang Z, Zeng H. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. Am J Med Sci 2014;347:131-8. [PMID: 23563307 DOI: 10.1097/MAJ.0b013e318286878d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
384 Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30:512-520. [PMID: 20102511 DOI: 10.1111/j.1478-3231.2009.02198.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
385 Wang K, Liu H, He Y, Chen T, Yang Y, Niu Y, Chen H, Chen Y, Liu J, Ye F, Lin S, Zhao Y. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Human Immunology 2010;71:950-6. [DOI: 10.1016/j.humimm.2010.07.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
386 Zhang X, Liu L, Zhang M, Gao S, Du Y, An Y, Chen S. The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. Annals of Hepatology 2015;14:150-60. [DOI: 10.1016/s1665-2681(19)30776-8] [Cited by in Crossref: 12] [Article Influence: 1.7] [Reference Citation Analysis]
387 Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62-72. [PMID: 21254162 DOI: 10.1002/hep.23952] [Cited by in Crossref: 218] [Cited by in F6Publishing: 199] [Article Influence: 18.2] [Reference Citation Analysis]
388 Eidi Nita M, Gaburo N, Cheinquer H, L’ltalien G, Stanislau Affonso de Araujo E, Mantilla P, Cure-bolt N, Lotufo PA. Patterns of viral load in chronic hepatitis B patients in Brazil and their association with ALT levels and HBeAg status. Annals of Hepatology 2009;8:339-45. [DOI: 10.1016/s1665-2681(19)31747-8] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
389 Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf. 2015;14:389-399. [PMID: 25518908 DOI: 10.1517/14740338.2015.993605] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
390 Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012;56:520-526. [PMID: 22037226 DOI: 10.1016/j.jhep.2011.09.018] [Cited by in Crossref: 91] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
391 Hahné SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar Mv. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. [PMID: 23597411 DOI: 10.1186/1471-2334-13-181] [Cited by in Crossref: 142] [Cited by in F6Publishing: 136] [Article Influence: 15.8] [Reference Citation Analysis]
392 Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454-461. [PMID: 20683945 DOI: 10.1002/hep.23722] [Cited by in Crossref: 170] [Cited by in F6Publishing: 155] [Article Influence: 14.2] [Reference Citation Analysis]
393 Ke WM, Xie SB, Li XJ, Zhang SQ, Lai J, Ye YN, Gao ZL, Chen PJ. There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume. J Viral Hepat. 2011;18:637-645. [PMID: 21794025 DOI: 10.1111/j.1365-2893.2011.01444.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
394 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012;9:156-166. [PMID: 22271089 DOI: 10.1038/nrclinonc.2012.1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 10.7] [Reference Citation Analysis]
395 Boyd A, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-691. [PMID: 27210429 DOI: 10.1016/j.jhep.2016.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
396 Wang J, Ma YJ, Tang H. Optimal strategy for antiviral therapy of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2010; 18(28): 2985-2991 [DOI: 10.11569/wcjd.v18.i28.2985] [Reference Citation Analysis]
397 Seo YS, Kim MN, Kim SU, Kim SG, Um SH, Han KH, Kim YS. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. Medicine (Baltimore). 2016;95:e2985. [PMID: 27015173 DOI: 10.1097/md.0000000000002985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
398 Li X, Lin Q, Dong M, Wen J, Wei L, Ma X, Chen Z, Wu X. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leukemia & Lymphoma 2010;51:1678-85. [DOI: 10.3109/10428194.2010.499486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
399 Zhang Z, Wang G, Kang K, Wu G, Wang P. Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep 2016;6:32875. [PMID: 27597515 DOI: 10.1038/srep32875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
400 Celik M, Arabul M, Cekiç C, Vatansever S, Ipek S, Aslan F, Unsal B. Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection. Prz Gastroenterol 2014;9:164-7. [PMID: 25097714 DOI: 10.5114/pg.2014.43758] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
401 Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
402 Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, Zhang X, Shen J, Wu M, Yan Y. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:158-164. [PMID: 21871026 DOI: 10.1111/j.1440-1746.2011.06888.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
403 Chaulet P. Tuberculosis: a six-month cure. World Health Forum. 1989;10:116-122. [PMID: 2665766 DOI: 10.1016/j.critrevonc.2015.10.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
404 Kim HJ, Cho YK, Jeon WK, Kim BI. Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. Clin Mol Hepatol 2017;23:323-30. [PMID: 28870025 DOI: 10.3350/cmh.2017.0005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
405 Sun YT, Zhang YX, Tang H, Mao Q, Wang XZ, Zhang LY, Chen H, Zhong YN, Lin SM, Zhang DZ. Clinical characteristics and current management of hepatitis B and C in China. World J Gastroenterol 2014; 20(37): 13582-13590 [PMID: 25309089 DOI: 10.3748/wjg.v20.i37.13582] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
406 Minami M. Future therapy for hepatitis B virus infection. Clin J Gastroenterol. 2015;8:167-171. [PMID: 26265385 DOI: 10.1007/s12328-015-0590-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
407 Karabay O, Tuna N, Yahyaoglu M. Hepatitis B viral breakthrough associated with inappropriate preservation of entecavir. Indian J Pharmacol 2012;44:136-7. [PMID: 22345891 DOI: 10.4103/0253-7613.91889] [Reference Citation Analysis]
408 Bruno R, Carosi G, Coppola N, Gaeta GB, Puoti M, Santantonio T, Taliani G, Armignacco O, Sagnelli E, Andreoni M, Angarano G, Di Perri G, D'Offizi G, Galli M, Rizzardini G; Italian Society for the Study of Infectious and Tropical Diseases. Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT). Infection 2014;42:811-5. [PMID: 24997980 DOI: 10.1007/s15010-014-0642-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
409 Bayard F, Godon O, Nalpas B, Costentin C, Zhu R, Soussan P, Vallet-Pichard A, Fontaine H, Mallet V, Pol S. T-cell responses to hepatitis B splice-generated protein of hepatitis B virus and inflammatory cytokines/chemokines in chronic hepatitis B patients. ANRS study: HB EP 02 HBSP-FIBRO. J Viral Hepat. 2012;19:872-880. [PMID: 23121366 DOI: 10.1111/j.1365-2893.2012.01611.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
410 Okoror LE, Ajayi AO, Ijalana OB. Elevated serum β2-microglobulin in individuals coinfected with hepatitis B and hepatitis D virus in a rural settings in Southwest Nigeria. BMC Res Notes 2017;10:719. [PMID: 29221492 DOI: 10.1186/s13104-017-3015-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
411 Mao QG, Pan JS, Fang KN, Zhang RM, Hong QY, Song MN, Zhu JP, Huang WQ, Chen LM, Hong MZ. Precise prediction model and simplified scoring system for sustained combined response to interferon-α. World J Gastroenterol 2010; 16(27): 3465-3471 [PMID: 20632453 DOI: 10.3748/wjg.v16.i27.3465] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
412 Roche B, Samuel D. Hepatitis: viral load predicts HBV recurrence after liver transplant. Nat Rev Gastroenterol Hepatol. 2010;7:657-658. [PMID: 21124520 DOI: 10.1038/nrgastro.2010.165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
413 Li L, Liu W, Chen YH, Fan CL, Dong PL, Wei FL, Li B, Chen DX, Ding HG. Antiviral drug resistance increases hepatocellular carcinoma: A prospective decompensated cirrhosis cohort study. World J Gastroenterol 2013; 19(45): 8373-8381 [PMID: 24363530 DOI: 10.3748/wjg.v19.i45.8373] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
414 Boglione L, D'avolio A, Cariti G, Milia MG, Simiele M, De Nicolò A, Ghisetti V, Di Perri G. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013;20:e11-9. [DOI: 10.1111/jvh.12018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
415 Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, Yoo BC. A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. J Gut Liver. 2010;4:530-536. [PMID: 21253304 DOI: 10.5009/gnl.2010.4.4.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
416 Huang H, Sun Z, Pan H, Chen M, Tong Y, Zhang J, Chen D, Su X, Li L. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep 2016;6:30853. [PMID: 27498553 DOI: 10.1038/srep30853] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
417 Choung BS, Kim IH, Jeon BJ, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG. Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B. Gut Liver. 2012;6:486-492. [PMID: 23170155 DOI: 10.5009/gnl.2012.6.4.486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
418 Fung J, Lai CL, Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther. 2010;8:717-726. [PMID: 20521898 DOI: 10.1586/eri.10.45] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
419 Zheng Q, Zhu YY, Chen J, Liu YR, You J, Dong J, Zeng DW, Gao LY, Chen LH, Jiang JJ. Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss. J Viral Hepat. 2014;21:909-916. [PMID: 24888640 DOI: 10.1111/jvh.12261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
420 Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52. [PMID: 21819330 DOI: 10.1586/eri.11.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
421 Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 2013;41:D566-D570. [PMID: 23125365 DOI: 10.1093/nar/gks1022] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 11.5] [Reference Citation Analysis]
422 Tabernero D, Sánchez MJ, Homs M, Rodríguez-frías F, Jardí R, Schaper M, Esteban R, Buti M. Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment: Hepatitis B mutations and therapy response. Alimentary Pharmacology & Therapeutics 2010;32:97-104. [DOI: 10.1111/j.1365-2036.2010.04319.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
423 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 165] [Article Influence: 15.5] [Reference Citation Analysis]
424 Ridruejo E, Adrover R, Mandó OG, Silva MO. Entecavir in the treatment of chronic hepatitis B in kidney transplantation. J Hepatol. 2012;56:997-998; author reply 999. [PMID: 22075262 DOI: 10.1016/j.jhep.2011.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
425 Pérez-Molina JA, Herrero-Martínez JM, Norman F, Pérez-Ayala A, Monge-Mahillo B, Navarro-Beltrá M, López-Vélez R. Clinical, epidemiological characteristics and indications for liver biopsy and treatment in immigrants with chronic hepatitis B at a referral hospital in Madrid. J Viral Hepat 2011;18:294-9. [PMID: 20367791 DOI: 10.1111/j.1365-2893.2010.01306.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
426 Feuchtenberger M, Schäfer A, Philipp Nigg A, Rupert Kraus M. Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J 2016;10:39-48. [PMID: 27708728 DOI: 10.2174/1874312901610010039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
427 Kose S, Tatar B, Gül S, Pala E. The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. Acta Clin Belg 2016;71:244-9. [PMID: 27075801 DOI: 10.1080/17843286.2015.1118183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
428 Wedemeyer H. Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV. Journal of Hepatology 2010;52:627-9. [DOI: 10.1016/j.jhep.2010.02.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
429 Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:5-15. [PMID: 19763714 DOI: 10.1007/s12072-009-9149-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
430 Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan H, Sung JJ, Chan HL. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. Journal of Hepatology 2011;54:236-42. [DOI: 10.1016/j.jhep.2010.06.043] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
431 Sombie R, Bougouma A, Somda S, Sangare L, Lompo O, Kabore Z, Tieno H, Drabo J, Ilboudo D. Hépatite C chronique: épidémiologie, diagnostic et traitement au CHU Yalgado-Ouédraogo de Ouagadougou. J Afr Hepato Gastroenterol 2011;5:6-13. [DOI: 10.1007/s12157-010-0213-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
432 Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother. 2010;11:919-928. [PMID: 20166841 DOI: 10.1517/14656561003637659] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
433 Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience. J Gastroenterol Hepatol 2012;27:1447-53. [PMID: 22168789 DOI: 10.1111/j.1440-1746.2011.07051.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
434 Tacke F, Shirvani-Dastgerdi E. Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro. Hepat Mon 2012;12:357-60. [PMID: 22879823 DOI: 10.5812/hepatmon.6131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
435 Wong GL, Wong VW, Chim AM, Yiu KK, Chu SH, Li MK, Chan HL. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011;26:300-5. [PMID: 21261720 DOI: 10.1111/j.1440-1746.2010.06510.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 8.9] [Reference Citation Analysis]
436 Singla B, Bhattacharyya R, Chakraborti A, Sharma BK, Kapil S, Chawla YK, Arora SK, Das A, Dhiman RK, Duseja A. Response to potent anti-HBV agents in chronic hepatitis B and combined effect of HBV reverse transcriptase mutations. Gene 2015;567:22-30. [PMID: 25917965 DOI: 10.1016/j.gene.2015.04.060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17(12): 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
438 Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2012;19:220-226. [PMID: 22329377 DOI: 10.1111/j.1365-2893.2011.01542.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
439 Shen T, Yan XM. Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol 2014; 20(18): 5435-5441 [PMID: 24833874 DOI: 10.3748/wjg.v20.i18.5435] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
440 Dan YY, Wong JB, Hamid SS, Han KH, Jia JD, Liu CJ, Piratvisuth T, Lok AS, Lim SG. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatol Int. 2014;8:382-394. [PMID: 26202640 DOI: 10.1007/s12072-014-9549-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
441 Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264-1271. [PMID: 21364549 DOI: 10.1038/ajg.2011.45] [Cited by in Crossref: 108] [Cited by in F6Publishing: 103] [Article Influence: 9.8] [Reference Citation Analysis]
442 Coppola N, Masiello A, Tonziello G, Pisapia R, Pisaturo M, Sagnelli C, Messina V, Iodice V, Sagnelli E. Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. J Viral Hepat. 2010;17:493-500. [PMID: 19780943 DOI: 10.1111/j.1365-2893.2009.01201.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
443 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
444 Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Guillaume S, Hachulla E, Masson C, Morel J, Puéchal X, Saraux A, Schaeverbeke T, Wendling D, Bruckert E, Pol S, Mariette X, Sibilia J; Club Rhumatismes et Inflammation (CRI). Tocilizumab: therapy and safety management. Joint Bone Spine 2010;77 Suppl 1:S3-100. [PMID: 20610315 DOI: 10.1016/S1297-319X(10)70001-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
445 Pawłowska M, Halota W, Smukalska E, Woźniakowska-Gęsicka T, Kupś J. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2012;31:571-4. [PMID: 21796345 DOI: 10.1007/s10096-011-1349-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
446 Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138-143. [PMID: 21199525 DOI: 10.1111/j.1440-1746.2010.06545.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 9.4] [Reference Citation Analysis]
447 Jian ZW, Wu XW, Chen ZX, Wang JC, Peng JY, Lao XM. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 2019;64:2187-98. [PMID: 30815819 DOI: 10.1007/s10620-019-05543-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
448 Kim DY, Song KJ, Kim SU, Yoo EJ, Park JY, Ahn SH, Han KH. Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Onco Targets Ther. 2013;6:1463-1469. [PMID: 24204161 DOI: 10.2147/ott.s51986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
449 Li P, Tan H, Xu D, Yin F, Cheng Y, Zhang X, Liu Y, Wang F. Effect and mechanisms of curdlan sulfate on inhibiting HBV infection and acting as an HB vaccine adjuvant. Carbohydrate Polymers 2014;110:446-55. [DOI: 10.1016/j.carbpol.2014.04.025] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
450 García Buey L, González Mateos F, Moreno-otero R. Cirrosis hepática. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:625-33. [DOI: 10.1016/s0304-5412(12)70359-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
451 Pan CQ, Hu K, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir: Tenofovir for entecavir suboptimal response. Journal of Viral Hepatitis 2012;19:213-9. [DOI: 10.1111/j.1365-2893.2011.01533.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
452 Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, Wang L, Mao P, Zoulim F. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat. 2010;17:887-895. [PMID: 20070500 DOI: 10.1111/j.1365-2893.2009.01254.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
453 Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011;5:644-53. [PMID: 21484123 DOI: 10.1007/s12072-011-9261-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
454 De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2010;2:1279-305. [PMID: 21994680 DOI: 10.3390/v2061279] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
455 Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360-1368.e1. [PMID: 22537444 DOI: 10.1053/j.gastro.2012.01.044] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
456 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014; 20(43): 16053-16061 [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
457 Hockenbery DM, Strasser SI, Mcdonald GB. Gastrointestinal and Hepatic Complications. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. Chichester: John Wiley & Sons, Ltd; 2015. pp. 1140-60. [DOI: 10.1002/9781118416426.ch94] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
458 Strasser SI. Drugs in Development for the Treatment of Chronic Hepatitis B. Curr Hepatitis Rep 2012;11:111-8. [DOI: 10.1007/s11901-012-0131-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
459 Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology. 2010;138:522-530. [PMID: 19879275 DOI: 10.1053/j.gastro.2009.10.039] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 6.3] [Reference Citation Analysis]
460 Harigai M, Mochida S, Mimura T, Koike T, Miyasaka N. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014;24:1-7. [PMID: 24261752 DOI: 10.3109/14397595.2013.852834] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
461 Antaki N, Haffar S, Ali Deeb S, Assaad F, Abou Harb R, Zeibane N, Nasserelddine M, Ibrahim N, Alhaj N, Jabbour E, Aaraj R, Antaki F, Kebbewar K; Syrian Working Group for the Study of Viral Hepatitis. High prevalence of HBV genotype D in Syria and the clinical characteristics of hepatitis B e antigen-negative chronic hepatitis B. Epidemiol Infect 2010;138:40-4. [PMID: 19538827 DOI: 10.1017/S0950268809990288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
462 Purnak T, Beyazit Y, Oztas E, Yesil Y, Efe C, Torun S, Celik T, Tenlik I, Kurt M, Ozaslan E. Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B. J Renin Angiotensin Aldosterone Syst. 2012;13:244-249. [PMID: 22277254 DOI: 10.1177/1470320311434241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
463 Scoazec JY. [Liver biopsy: Which role in patient management?]. Ann Pathol 2010;30:464-9. [PMID: 21167433 DOI: 10.1016/j.annpat.2010.08.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
464 Vajro P, Veropalumbo C, Maddaluno S, Salerno M, Parenti G, Pignata C. Treatment of children with chronic viral hepatitis: what is available and what is in store. World J Pediatr 2013;9:212-20. [DOI: 10.1007/s12519-013-0426-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
465 Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012;27:306-312. [PMID: 21777281 DOI: 10.1111/j.1440-1746.2011.06852.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
466 Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, Luo G, Gao Z, Liu J, Jia G. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. J Viral Hepat. 2013;20 Suppl 1:58-64. [PMID: 23458526 DOI: 10.1111/jvh.12065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
467 Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update: Treatment guidelines for hepatitis B. Journal of Gastroenterology and Hepatology 2011;26:829-35. [DOI: 10.1111/j.1440-1746.2011.06623.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
468 Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat. 2012;19:1-8. [PMID: 22187942 DOI: 10.1111/j.1365-2893.2011.01548.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
469 Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver. 2014;8:64-69. [PMID: 24516703 DOI: 10.5009/gnl.2014.8.1.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
470 Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31-40. [PMID: 20051970 DOI: 10.1038/nrgastro.2009.205] [Cited by in Crossref: 224] [Cited by in F6Publishing: 180] [Article Influence: 18.7] [Reference Citation Analysis]
471 Boyd A, Lacombe K, Lavocat F, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F. Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. Antiviral Res 2018;149:174-8. [PMID: 29169914 DOI: 10.1016/j.antiviral.2017.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
472 Park JG, Park SY. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol 2015;21:242-8. [PMID: 26523269 DOI: 10.3350/cmh.2015.21.3.242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
473 Muñoz Bertrán E, Pérez Ceballos E, Gómez Espín R, Ortega González I. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab]. Gastroenterol Hepatol. 2010;33:377-381. [PMID: 20363054 DOI: 10.1016/j.gastrohep.2010.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
474 Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. J Viral Hepat. 2012;19:e41-e47. [PMID: 22239525 DOI: 10.1111/j.1365-2893.2011.01509.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
475 Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142:1303-1313.e1. [PMID: 22537437 DOI: 10.1053/j.gastro.2012.02.027] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 8.8] [Reference Citation Analysis]
476 Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr. 2012;55:648-652. [PMID: 22688509 DOI: 10.1097/mpg.0b013e318262a737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
477 Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57:196-202. [PMID: 22450396 DOI: 10.1016/j.jhep.2011.11.030] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
478 Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir vs adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91-100. [PMID: 21503940 DOI: 10.1002/hep.24361] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 13.0] [Reference Citation Analysis]
479 Sahin M, Karayakar F, Koksal AR, Yetim A, İyisoy MS, Şen İ, Alkım H, Alkım C, Colak T. Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment. Biol Trace Elem Res 2019;188:245-50. [PMID: 29926391 DOI: 10.1007/s12011-018-1414-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
480 Emara MH, El-Gammal NE, Mohamed LA, Bahgat MM. Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy. Virol J. 2010;7:324. [PMID: 21083926 DOI: 10.1186/1743-422x-7-324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
481 Miquel M, Núñez Ó, Trapero-marugán M, Díaz-sánchez A, Jiménez M, Arenas J, Canós AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Annals of Hepatology 2013;12:205-12. [DOI: 10.1016/s1665-2681(19)31358-4] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
482 Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143:619-28.e1. [PMID: 22643350 DOI: 10.1053/j.gastro.2012.05.037] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 10.2] [Reference Citation Analysis]
483 Thompson PA, Tam CS, Thursky K, Seymour JF. Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma 2010;51:1592-5. [PMID: 20807092 DOI: 10.3109/10428194.2010.509456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
484 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
485 Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One 2013;8:e68780. [PMID: 23874760 DOI: 10.1371/journal.pone.0068780] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 8.7] [Reference Citation Analysis]
486 Chen X, Cao Z, Liu Y, Zhang H, Zhang Y, Ma L, Jin Y, Yu H, Ma B, Zheng Y, Wu H. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol 2012;27:481-6. [PMID: 22098411 DOI: 10.1111/j.1440-1746.2011.06970.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
487 Fox M, Fox J, Davies M. Diagnosis and management of chronic liver disease in older people. Rev Clin Gerontol 2011;21:1-15. [DOI: 10.1017/s0959259810000365] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
488 Ferreira SC, Chachá SG, Souza FF, Teixeira AC, Santana RC, Villanova MG, Zucoloto S, Ramalho LN, Perdoná GS, Passos AD, Martinelli AL. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Annals of Hepatology 2014;13:762-70. [DOI: 10.1016/s1665-2681(19)30978-0] [Cited by in Crossref: 17] [Article Influence: 2.1] [Reference Citation Analysis]
489 Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon 2013;13:e8743. [PMID: 24066002 DOI: 10.5812/hepatmon.8743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
490 Viganò M, Paggi S, Lampertico P, Fraquelli M, Massironi S, Ronchi G, Rigamonti C, Conte D, Colombo M. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther. 2011;34:353-362. [PMID: 21631559 DOI: 10.1111/j.1365-2036.2011.04722.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 5.5] [Reference Citation Analysis]
491 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012;55:68-76. [PMID: 21858846 DOI: 10.1002/hep.24615] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 9.6] [Reference Citation Analysis]
492 Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci. 2012;57:221-231. [PMID: 21743991 DOI: 10.1007/s10620-011-1816-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
493 De Paschale M, Manco MT, Belvisi L, Magnani C, Re T, Viganò P, Biagiotti S, Capelli F, Mazzone A, Baldacci MP, Ferrara A, Neri AL, Guastoni CM, Bonazzina RA, Brando B, Clerici P. Epidemiology of hepatitis D virus (HDV) infection in an urban area of northern Italy. Infection 2012;40:485-91. [PMID: 22367777 DOI: 10.1007/s15010-012-0247-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
494 Mendes-Correa MC, Pinho JR, Gomes-Gouvea MS, da Silva AC, Guastini CF, Martins LG, Leite AG, Silva MH, Gianini RJ, Uip DE. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. BMC Infect Dis 2011;11:247. [PMID: 21933423 DOI: 10.1186/1471-2334-11-247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
495 Jia W, Qi X, Ji YY, Xun YH, Wang H, Zhang WH, Yang JH, Wang JY, Zhu HX, Mao RC, Zhang JM. Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China. Hepat Mon 2015;15:e29183. [PMID: 26322110 DOI: 10.5812/hepatmon.29183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
496 Ha M, Zhang G, Diao S, Lin M, Sun L, She H, Kuan C, Shen L, Huang C, Shen W. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol. 2012;157:285-290. [PMID: 22080196 DOI: 10.1007/s00705-011-1163-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
497 Wang Y, Xu MY, Zheng RD, Xian JC, Xu HT, Shi JP, Li SB, Qu Y, Dong YW, Lu LG. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatol Res. 2013;43:441-451. [PMID: 23006433 DOI: 10.1111/j.1872-034x.2012.01094.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
498 Morando F, Maresio G, Piano S, Fasolato S, Cavallin M, Romano A, Rosi S, Gola E, Frigo AC, Stanco M, Destro C, Rupolo G, Mantoan D, Gatta A, Angeli P. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol. 2013;59:257-264. [PMID: 23523582 DOI: 10.1016/j.jhep.2013.03.010] [Cited by in Crossref: 104] [Cited by in F6Publishing: 86] [Article Influence: 11.6] [Reference Citation Analysis]
499 Mikulska M, Taramasso L, Giacobbe DR, Caligiuri P, Bruzzone B, Di Biagio A, Viscoli C. Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. J Med Virol. 2012;84:1340-1343. [PMID: 22825811 DOI: 10.1002/jmv.23338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
500 Ali S, Mealing S, Hawkins N, Lescrauwaet B, Bjork S, Mantovani L, Lampertico P. The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. BMJ Open 2013;3:e001309. [PMID: 23355658 DOI: 10.1136/bmjopen-2012-001309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
501 Cainelli F, Vento S. Time for universal HIV and HBV screening for patients with cancer. The Lancet Oncology 2010;11:916-8. [DOI: 10.1016/s1470-2045(10)70197-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
502 Ocama P, Castelnuovo B, Kamya MR, Kirk GD, Reynolds SJ, Kiragga A, Colebunders R, Thomas DL. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. Int J STD AIDS. 2010;21:553-557. [PMID: 20975087 DOI: 10.1258/ijsa.2010.010027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
503 Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12:193-207. [DOI: 10.1517/14712598.2012.646986] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
504 Tong CY, Cane PA, Pillay D. ARHAI: antiviral resistance. J Antimicrob Chemother 2012;67 Suppl 1:i65-8. [PMID: 22855880 DOI: 10.1093/jac/dks197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
505 Kang NL, Zhang JM, Liu YR, Lin S, Dong J, Jiang JJ, Zhu YY, Zeng DW. Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. Clin Res Hepatol Gastroenterol. 2020;44:57-65. [PMID: 31076363 DOI: 10.1016/j.clinre.2019.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
506 Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359-371. [PMID: 22033451 DOI: 10.1097/md.0b013e3182380a76] [Cited by in Crossref: 197] [Cited by in F6Publishing: 59] [Article Influence: 19.7] [Reference Citation Analysis]
507 Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. World J Gastroenterol 2013; 19(44): 7867-7873 [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
508 Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 2009;50:1064-1071. [PMID: 19637288 DOI: 10.1002/hep.23145] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
509 Han GR, Xu CL, Zhao W, Yang YF. Management of chronic hepatitis B in pregnancy. World J Gastroenterol 2012; 18(33): 4517-4521 [PMID: 22969224 DOI: 10.3748/wjg.v18.i33.4517] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
510 Crespo G, Mariño Z, Navasa M, Forns X. Viral Hepatitis in Liver Transplantation. Gastroenterology 2012;142:1373-1383.e1. [DOI: 10.1053/j.gastro.2012.02.011] [Cited by in Crossref: 149] [Cited by in F6Publishing: 128] [Article Influence: 14.9] [Reference Citation Analysis]
511 Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol. 2010;8:535-540. [PMID: 20304099 DOI: 10.1016/j.cgh.2010.03.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
512 Pan XC, Ren JS. Antiviral therapy in patients with concomitant chronic hepatitis B and autoimmune diseases. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1629-1633 [DOI: 10.11569/wcjd.v19.i15.1629] [Reference Citation Analysis]
513 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
514 Ramos-casals M. Are TNF blockers safe for patients with hepatitis B virus infection? Nat Rev Rheumatol 2010;6:618-20. [DOI: 10.1038/nrrheum.2010.156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
515 Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A. Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2010;16:809-17. [DOI: 10.1016/j.bbmt.2009.12.533] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
516 Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis 2013;17:489-501. [PMID: 23905818 DOI: 10.1016/j.cld.2013.05.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
517 Lao X, Wang D, Shi M, Liu G, Li S, Guo R, Yuan Y, Chen M, Li J, Zhang Y, Lin X. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma: HBV DNA and liver function after TACE. Hepatology Research 2011;41:553-63. [DOI: 10.1111/j.1872-034x.2011.00796.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
518 Wei L, Hu S, Hou J, Liu G, Ren H, Duan Z, Xie Q, Fang X, Jia J. A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. Value Health Reg Issues 2013;2:48-56. [PMID: 29702852 DOI: 10.1016/j.vhri.2013.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
519 Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427-433. [PMID: 23471472 DOI: 10.7150/ijms.5472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
520 Stroffolini T, Spadaro A, Di Marco V, Scifo G, Russello M, Montalto G, Bertino G, Surace L, Caroleo B, Foti G, Portelli V, Madonia S, Sapienza M, Cosco L, Frugiuele P, Galdieri A, Brandolino N, Siciliano R, Bruno S, Almasio PL; Gr.E.Ca.S. Hospitals' Collaborating Group. Current practice of chronic hepatitis B treatment in Southern Italy. Eur J Intern Med 2012;23:e124-7. [PMID: 22726382 DOI: 10.1016/j.ejim.2012.03.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
521 Zhang Z, Wang G, Kang K, Wu G, Wang P. The Diagnostic Accuracy and Clinical Utility of Three Noninvasive Models for Predicting Liver Fibrosis in Patients with HBV Infection. PLoS One 2016;11:e0152757. [PMID: 27050531 DOI: 10.1371/journal.pone.0152757] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
522 Rajbhandari R, Danford CJ, Chung RT, Ananthakrishnan AN. HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease. Aliment Pharmacol Ther 2015;41:928-38. [PMID: 25786514 DOI: 10.1111/apt.13162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
523 Huang R, Hao Y, Zhang J, Wu C. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res 2013;43:1040-51. [PMID: 23356962 DOI: 10.1111/hepr.12058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
524 Liu Y, Zhong Y, Zou Z, Xu Z, Li B, Ren X, Bai S, Wang L, Li X, Dai J. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol. 2010;47:243-247. [PMID: 20080060 DOI: 10.1016/j.jcv.2009.12.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
525 Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005. [PMID: 19454492 DOI: 10.3324/haematol.2009.005819] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
526 Utsumi T, Yano Y, Hotta H. Molecular epidemiology of hepatitis B virus in Asia. World J Med Genet 2014; 4(2): 19-26 [DOI: 10.5496/wjmg.v4.i2.19] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
527 Ismail AM, Samuel P, Ramachandran J, Eapen CE, Kannangai R, Abraham P. Lamivudine Monotherapy in Chronic Hepatitis B Patients from the Indian Subcontinent: Antiviral Resistance Mutations and Predictive Factors of Treatment Response. Mol Diagn Ther 2014;18:63-71. [DOI: 10.1007/s40291-013-0054-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
528 Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013;58:225-233. [PMID: 23046671 DOI: 10.1016/j.jhep.2012.09.029] [Cited by in Crossref: 140] [Cited by in F6Publishing: 140] [Article Influence: 14.0] [Reference Citation Analysis]
529 Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirotchanakul S, Phisalprapa P, Tanwandee T, Wursthorn K, Brunetto MR, Wedemeyer H. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol. 2011;18:1943-1950. [PMID: 21880853 DOI: 10.1128/cvi.05122-11] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
530 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
531 Vallet-Pichard A, Mallet V, Costentin CE, Pol S. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther. 2009;7:527-535. [PMID: 19485793 DOI: 10.1586/eri.09.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
532 Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol. 2015;62:S38-S46. [PMID: 25920088 DOI: 10.1016/j.jhep.2015.03.006] [Cited by in Crossref: 152] [Cited by in F6Publishing: 136] [Article Influence: 25.3] [Reference Citation Analysis]
533 Liu H, Liu Y, Wang L, Xu D, Lin B, Zhong R, Gong S, Podda M, Invernizzi P. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol. 2010;10:100. [PMID: 20815889 DOI: 10.1186/1471-230x-10-100] [Cited by in Crossref: 54] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
534 Yang Y, Xiong Q, Zhao W, Zhong Y. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. Clinics and Research in Hepatology and Gastroenterology 2012;36:e89-92. [DOI: 10.1016/j.clinre.2012.03.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
535 Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol 2018;31:632-8. [PMID: 30285571 DOI: 10.1089/vim.2018.0022] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
536 Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. J Viral Hepat 2013;20:52-7. [DOI: 10.1111/jvh.12064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
537 Zhong Y, Han J, Zou Z, Liu S, Tang B, Ren X, Li X, Zhao Y, Liu Y, Zhou D. Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR. Clin Chim Acta. 2011;412:1905-1911. [PMID: 21741960 DOI: 10.1016/j.cca.2011.06.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
538 Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann HL, Rosenau J, Bock CT. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012;56:115-122. [PMID: 21762665 DOI: 10.1016/j.jhep.2011.06.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
539 Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol. 2013;85:55-64. [PMID: 23096938 DOI: 10.1002/jmv.23440] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
540 Hung H, Su C, Wu J, Lee S. Reactivation of hepatitis B virus after transarterial chemo-embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. Journal of Hepatology 2010;52:463-5. [DOI: 10.1016/j.jhep.2009.11.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
541 Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Adv Ther 2015;32:727-41. [PMID: 26329749 DOI: 10.1007/s12325-015-0232-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
542 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
543 Grimm D, Heeg M, Thimme R. Hepatitis B virus: from immunobiology to immunotherapy. Clin Sci (Lond). 2013;124:77-85. [PMID: 23013042 DOI: 10.1042/CS20120169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
544 Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J. 2009;6:163. [PMID: 19818142 DOI: 10.1186/1743-422x-6-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
545 Locarnini S. Transmission of antiviral drug resistant hepatitis B virus: Implications for public health and patient management. Journal of Gastroenterology and Hepatology 2010;25:649-51. [DOI: 10.1111/j.1440-1746.2010.06255.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
546 Amini-Bavil-Olyaee S, Pourkarim MR, Schaefer S, Mahboudi F, Van Ranst M, Adeli A, Trautwein C, Tacke F. Single-step real-time PCR to quantify hepatitis B virus and distinguish genotype D from non-D genotypes. J Viral Hepat. 2011;18:300-304. [PMID: 20367802 DOI: 10.1111/j.1365-2893.2010.01308.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
547 Jansen TL, Mulder CJ. Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers. Expert Opin Biol Ther 2012;12:391-3. [PMID: 22413822 DOI: 10.1517/14712598.2012.666521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
548 Wang F, Jing X, Li G, Wang T, Yang B, Zhu Z, Gao Y, Zhang Q, Yang Y, Wang Y, Wang P, Du Z. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. Liver Int. 2012;32:644-655. [PMID: 22118340 DOI: 10.1111/j.1478-3231.2011.02675.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
549 Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance. J Med Virol. 2012;84:424-430. [PMID: 22246827 DOI: 10.1002/jmv.23229] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
550 Burns K, Heslin J, Crowley B, Thornton L, Laoi BN, Kelly E, Ward E, Doody B, Hickey MM. Nosocomial outbreak of hepatitis B virus infection involving two hospitals in the Republic of Ireland. J Hosp Infect. 2011;78:279-283. [PMID: 21530000 DOI: 10.1016/j.jhin.2011.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
551 Thibault V, Gaudy-Graffin C, Colson P, Gozlan J, Schnepf N, Trimoulet P, Pallier C, Saune K, Branger M, Coste M, Thoraval FR; ANRS Multivir-HBV group. Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. Virol J 2013;10:87. [PMID: 23497042 DOI: 10.1186/1743-422X-10-87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
552 Zhu CW, Wang HY, Fang H. Antiviral therapy in patients with hepatitis B virus-related cirrhosis. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1592-1597 [DOI: 10.11569/wcjd.v19.i15.1592] [Reference Citation Analysis]
553 Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014;21:430-8. [PMID: 24750297 DOI: 10.1111/jvh.12161] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
554 Wandeler G, Musukuma K, Zürcher S, Vinikoor MJ, Llenas-García J, Aly MM, Mulenga L, Chi BH, Ehmer J, Hobbins MA, Bolton-Moore C, Hoffmann CJ, Egger M; IeDEA-Southern Africa. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. PLoS One 2016;11:e0152043. [PMID: 27032097 DOI: 10.1371/journal.pone.0152043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
555 Gao R, Gao F, Li G, Hao JY. Health-related quality of life in chinese patients with chronic liver disease. Gastroenterol Res Pract. 2012;2012:516140. [PMID: 22701477 DOI: 10.1155/2012/516140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
556 Du LY, Cui YL, Chen EQ, Cheng X, Liu L, Tang H. Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. Virol J 2014;11:51. [PMID: 24636575 DOI: 10.1186/1743-422X-11-51] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
557 Zhang M, Li Y, Fan Z, Shen D, Huang X, Yu Q, Liu M, Ren F, Wang X, Dai L, Wang P, Ye H, Shi J, Yang X, Zhang S, Zhang J. Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. BMJ Open 2021;11:e047475. [PMID: 34526336 DOI: 10.1136/bmjopen-2020-047475] [Reference Citation Analysis]
558 Ko SY, Oh HB, Park CW, Lee HC, Lee JE. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect. 2012;18:E404-E411. [PMID: 22757653 DOI: 10.1111/j.1469-0691.2012.03951.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
559 Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136:2169-2179.e1-4. [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006] [Cited by in Crossref: 234] [Cited by in F6Publishing: 209] [Article Influence: 18.0] [Reference Citation Analysis]
560 Holomán J, Glasa J. EASL clinical practice guidelines. J Hepatol. 2009;51:821-822. [PMID: 19576653 DOI: 10.1016/j.jhep.2009.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
561 Zhong Y, Tan F, Li M, Liu J, Wang X, Yuan Y, Zhong X, Peng F. Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection. International Journal of Infectious Diseases 2014;20:31-6. [DOI: 10.1016/j.ijid.2013.11.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
562 Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol. 2011;17:268-273. [PMID: 22310791 DOI: 10.3350/kjhep.2011.17.4.268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
563 Uzun B, Şener AG, Güngör S, Afşar İ, Demirci M. Evaluation of hepatitis delta virus (HDV) infection in blood donors in western Turkey. Transfusion and Apheresis Science 2014;50:388-91. [DOI: 10.1016/j.transci.2014.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
564 Liu YR, Lin BB, Zeng DW, Zhu YY, Chen J, Zheng Q, Dong J, Jiang JJ. Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. BMC Gastroenterol 2014;14:145. [PMID: 25128299 DOI: 10.1186/1471-230X-14-145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
565 Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025-2040. [PMID: 21682661 DOI: 10.1517/14656566.2011.590474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
566 Al-Mahtab M, Akbar SM, Rahman S, Kamal M, Khan MS. Biochemical, virological, immunological and histopathological features of 702 incidentally detected chronic hepatitis B virus carriers in Bangladesh. Digestion 2012;86:1-5. [PMID: 22688441 DOI: 10.1159/000337529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
567 Fiorino S, Conti F, Gramenzi A, Loggi E, Cursaro C, Di Donato R, Micco L, Gitto S, Cuppini A, Bernardi M, Andreone P. Vitamins in the treatment of chronic viral hepatitis. Br J Nutr 2011;105:982-9. [PMID: 21255469 DOI: 10.1017/S0007114510004629] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
568 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
569 Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010. Hepatology. 2013;58:856-862. [PMID: 23359276 DOI: 10.1002/hep.26286] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
570 Albayrak A, Ertek M, Tasyaran MA, Pirim I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem Genet. 2011;49:258-269. [PMID: 21188498 DOI: 10.1007/s10528-010-9404-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
571 Causse X, Cadranel JF, Potier P, Hanslik B, Denis J, Renou C, Delasalle P; Club de Réflexion des Cabinets et Groupes d’Hépato-Gastroentérologie (CREGG)., Association Nationale des hépato-Gastroentérologues des Hôpitaux généraux de France (ANGH). Hepatogastroenterologists' knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France: results of a practice survey. Eur J Gastroenterol Hepatol 2015;27:544-9. [PMID: 25822863 DOI: 10.1097/MEG.0000000000000306] [Reference Citation Analysis]
572 Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat. 2012;19:724-731. [PMID: 22967104 DOI: 10.1111/j.1365-2893.2012.01599.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
573 Wang X, Zhao YR, Liu HL, Ma XH, Zhang Y, Yi RT. Insulin Resistance Predicts Virological Response to Interferon-α in Chronic Hepatitis B Patients. J Clin Gastroenterol 2016;50:506-12. [PMID: 26600183 DOI: 10.1097/MCG.0000000000000452] [Reference Citation Analysis]
574 Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235:355-367. [PMID: 25196558 DOI: 10.1002/path.4434] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
575 Giersch K, Dandri M. Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. J Clin Transl Hepatol. 2015;3:220-229. [PMID: 26623269 DOI: 10.14218/jcth.2015.00018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
576 Guo H, Liao M, Jin J, Zeng J, Li S, Schroeder DR, Zheng J, Zheng R, Chen S. How intrahepatic cholestasis affects liver stiffness in patients with chronic hepatitis B: a study of 1197 patients with liver biopsy. Eur Radiol 2020;30:1096-104. [PMID: 31673836 DOI: 10.1007/s00330-019-06451-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
577 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-1651471-2334-11-165] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
578 Lopez-Suñé E, Tuset M, Laguno M, Moreno A, Miró JM. [Characteristics of hepatitis and influenza antivirals: update 2009]. Enferm Infecc Microbiol Clin 2010;28:253.e1-17. [PMID: 20395018 DOI: 10.1016/j.eimc.2010.02.001] [Reference Citation Analysis]
579 Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol. 2010;52:778. [PMID: 20347500 DOI: 10.1016/j.jhep.2009.12.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
580 Nian X, Xu Z, Liu Y, Chen J, Li X, Xu D. Association between hepatitis B virus basal core promoter/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis. Hepatol Int 2016;10:606-15. [DOI: 10.1007/s12072-016-9716-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
581 Shih CA, Chen WC, Yu HC, Cheng JS, Lai KH, Hsu JT, Chen HC, Hsu PI. Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. PLoS One. 2015;10:e0132426. [PMID: 26274393 DOI: 10.1371/journal.pone.0132426] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
582 Bourlière M, Kahloun A, Gascou-Tessonnier G. Analogs and fibrosis regression in hepatitis B. Gastroenterol Clin Biol 2009;33:923-9. [PMID: 19640665 DOI: 10.1016/j.gcb.2009.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
583 Zhang XQ, Zhang HY, You JP, Mao Q. Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Virol J 2013;10:21. [PMID: 23320822 DOI: 10.1186/1743-422X-10-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
584 Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, Li S, Chen M. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol 2015;30:1032-9. [PMID: 25639513 DOI: 10.1111/jgh.12910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
585 Xu Z, Ren X, Liu Y, Li X, Bai S, Zhong Y, Wang L, Mao P, Wang H, Xin S, Wong VW, Chan HL, Zoulim F, Xu D. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol 2011;46:391-400. [PMID: 20848146 DOI: 10.1007/s00535-010-0315-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
586 Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology. 2012;56:1983-1992. [PMID: 22729954 DOI: 10.1002/hep.25915] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
587 Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016;23:154-169. [PMID: 25967226 DOI: 10.1111/jvh.12418] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
588 Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol. 2013;67:247-291. [PMID: 23886003 DOI: 10.1016/B978-0-12-405880-4.00007-X] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
589 Lee HA, Lee YS, Kim BK, Jung YK, Kim SU, Park JY, Kim JH, An H, Kim DY, Yim HJ, Ahn SH, Yeon JE, Byun KS, Han KH, Um SH, Seo YS. Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. Gut Liver 2021;15:420-9. [PMID: 32839362 DOI: 10.5009/gnl20101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
590 Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol. 2011;54:209-218. [PMID: 21095036 DOI: 10.1016/j.jhep.2010.07.009] [Cited by in Crossref: 124] [Cited by in F6Publishing: 133] [Article Influence: 10.3] [Reference Citation Analysis]
591 Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, Yatsuhashi H, Hayashi N, Ishikawa H, Seriu T, Omata M. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010;4:594-600. [PMID: 21063482 DOI: 10.1007/s12072-010-9185-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
592 Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis. 2010;14:495-504. [PMID: 20638027 DOI: 10.1016/j.cld.2010.05.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
593 Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 2014;3:693-9. [DOI: 10.1586/egh.09.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
594 Wong VW, Sung JJ. Diagnosis and personalized management of hepatitis B including significance of genotypes: . Current Opinion in Infectious Diseases 2012;25:570-7. [DOI: 10.1097/qco.0b013e328357f2f8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
595 Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Review of Anti-infective Therapy 2014;7:633-6. [DOI: 10.1586/eri.09.57] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
596 Wang H, Yan R, Zhou Y, Wang MS, Ruo GQ, Cheng MJ. Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients. Hepatol Int 2014;8:216-23. [DOI: 10.1007/s12072-013-9502-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
597 Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial: LAM-to-ETV switching treatment. Hepatology Research 2011;41:505-11. [DOI: 10.1111/j.1872-034x.2011.00807.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
598 Di Marco V, Capra M, Angelucci E, Borgna-pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L, Filosa A, Rund D, Gamberini MR, Cianciulli P, De Montalembert M, Gagliardotto F, Foster G, Grangè JD, Cassarà F, Iacono A, Cappellini MD, Brittenham GM, Prati D, Pietrangelo A, Craxì A, Maggio A; on behalf of the Italian Society for the Study of Thalassemia and Haemoglobinopathies and Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010;116:2875-83. [DOI: 10.1182/blood-2009-11-248724] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
599 Kwak MS, Cho EJ, Jang ES, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Digestion. 2011;84 Suppl 1:23-28. [PMID: 22156482 DOI: 10.1159/000333211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
600 Yu F, Wang Y, Yuan S, Ma J, Ma N, Zhang X, Liu X, Liu D. Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B. Scandinavian Journal of Gastroenterology 2013;48:745-51. [DOI: 10.3109/00365521.2013.779746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
601 Virizuela JA, Carratalà J, Aguado JM, Vicente D, Salavert M, Ruiz M, Ruiz I, Marco F, Lizasoain M, Jiménez-Fonseca P, Gudiol C, Cassinello J, Carmona-Bayonas A, Aguilar M, Cruz JJ. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol 2016;18:557-70. [PMID: 26577106 DOI: 10.1007/s12094-015-1442-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
602 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
603 Min L, Chen X, Ye Y, Zhang Q, Ru S, Li X. Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid Based Complement Alternat Med 2013;2013:767290. [PMID: 24282437 DOI: 10.1155/2013/767290] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
604 Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev. 2011;CD006002. [PMID: 22161394 DOI: 10.1002/14651858.cd006002.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
605 Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
606 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
607 Dienstag JL. Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye. Am J Gastroenterol 2010;105:1770-2. [PMID: 20686463 DOI: 10.1038/ajg.2010.187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
608 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis. 2011;11:165. [PMID: 21651820 DOI: 10.1186/1471-2334-11-165] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
609 Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value Health 2015;18:800-9. [PMID: 26409607 DOI: 10.1016/j.jval.2015.05.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
610 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
611 Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013;58:713-717. [PMID: 24183313 DOI: 10.1016/j.jcv.2013.09.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
612 Kim JD, Choi JY, Bae SH, Yoon SK, Yang JM, Han NI, Choi SW, Lee CD, Lee YS, Jung ES. Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology 2010;8:60-5. [DOI: 10.1016/j.cgh.2009.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
613 Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24:70-78. [PMID: 23928932 DOI: 10.1007/s00330-013-2978-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 106] [Article Influence: 12.3] [Reference Citation Analysis]
614 Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK;  REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568-574. [PMID: 21497551 DOI: 10.1016/s1470-2045(11)70077-8] [Cited by in Crossref: 366] [Cited by in F6Publishing: 146] [Article Influence: 33.3] [Reference Citation Analysis]
615 Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011;55:522-528. [PMID: 21147187 DOI: 10.1016/j.jhep.2010.11.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
616 Yang G, Han M, Chen F, Xu Y, Chen E, Wang X, Liu Y, Sun J, Hou J, Ning Q, Wang Z. Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China. Hepatol Int 2014;8:508-16. [DOI: 10.1007/s12072-014-9554-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
617 Soriano V, Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research 2013;100:435-8. [DOI: 10.1016/j.antiviral.2013.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
618 Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39. [PMID: 21203860 DOI: 10.1007/s11606-010-1569-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
619 Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
620 Janssen HL, Reijnders JG. Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us? J Hepatol. 2009;51:1-3. [PMID: 19443071 DOI: 10.1016/j.jhep.2009.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
621 Suárez E, Gila A, Figueruela B, Chueca N, Muñoz Rueda P, Puche B, Fraga E, García F, Martín JM, Andrade RJ, Nogales C, Romero-Gómez M, Salmerón J. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. Gastroenterol Hepatol 2011;34:69-74. [PMID: 21334762 DOI: 10.1016/j.gastrohep.2010.11.003] [Reference Citation Analysis]
622 de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, Koot M, Jansen PL, Beld MG, Lopatin U. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol. 2012;47:475-481. [PMID: 22263608 DOI: 10.3109/00365521.2011.648952] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
623 Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
624 Mbaye PS, Sarr A, Sire JM, Evra ML, Ba A, Daveiga J, Diallo A, Fall F, Chartier L, Simon F, Vray M. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load. PLoS One 2011;6:e22291. [PMID: 21799814 DOI: 10.1371/journal.pone.0022291] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
625 Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012;32:544-553. [PMID: 22099371 DOI: 10.1111/j.1478-3231.2011.02682.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
626 Giersch K, Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M. Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. Gut 2019;68:150-7. [PMID: 29217749 DOI: 10.1136/gutjnl-2017-314713] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
627 Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
628 Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H. Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol. 2013;48:397-404. [PMID: 22850869 DOI: 10.1007/s00535-012-0645-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
629 Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014;58:1730-1737. [PMID: 24395227 DOI: 10.1128/aac.02483-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
630 Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, Kronenberger B, Piiper A. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat. 2012;19:e58-e65. [PMID: 22239527 DOI: 10.1111/j.1365-2893.2011.01536.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 7.7] [Reference Citation Analysis]
631 Juniastuti, Utsumi T, Aksono EB, Yano Y, Soetjipto, Hayashi Y, Hotta H, Rantam FA, Kusumobroto HO, Lusida MI. Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia. Biomed Rep 2013;1:522-8. [PMID: 24648979 DOI: 10.3892/br.2013.106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
632 Wang Z, Sun L, Wu Y, Xia Q. Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2016;40:195-202. [PMID: 26299874 DOI: 10.1016/j.clinre.2015.06.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
633 Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399-1408. [PMID: 27638356 DOI: 10.1016/s1473-3099(16)30204-3] [Cited by in Crossref: 167] [Cited by in F6Publishing: 81] [Article Influence: 27.8] [Reference Citation Analysis]
634 Ridruejo E, Díaz C, Dávalos Michel M, Soler Pujol G, Martínez A, Marciano S, Mandó OG, Vilches A. Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. Annals of Hepatology 2010;9:271-7. [DOI: 10.1016/s1665-2681(19)31636-9] [Cited by in Crossref: 15] [Article Influence: 1.3] [Reference Citation Analysis]
635 Cornberg M, Manns M. Leitliniengerechte Therapie der Hepatitis B. Korrekte Indikationsstellung ist die Voraussetzung. Pharmazie in unserer Zeit 2011;40:45-51. [DOI: 10.1002/pauz.201100399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
636 Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ. Genotypic resistance to entecavir in chronic hepatitis B patients. Korean J Hepatol 2010;16:147. [DOI: 10.3350/kjhep.2010.16.2.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
637 Tseng T, Liu C, Su T, Yang H, Wang C, Chen C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases 2012;206:1521-31. [DOI: 10.1093/infdis/jis569] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
638 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 41.1] [Reference Citation Analysis]
639 Pár A. [Hepatitis B virus (HBV) infection and hepatocarcinogenesis]. Orv Hetil. 2010;151:1045-1053. [PMID: 20558351 DOI: 10.1556/OH.2010.28881] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
640 Chen CC, Wang PC, Chang HW, Chen CF. Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation. J Viral Hepat. 2012;19:161-172. [PMID: 22329370 DOI: 10.1111/j.1365-2893.2011.01469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
641 Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, Cornberg M, Manns MP, Wedemeyer H. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. Journal of Clinical Virology 2011;50:292-6. [DOI: 10.1016/j.jcv.2010.12.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 5.8] [Reference Citation Analysis]
642 Nooredinvand HA, Connell DW, Asgheddi M, Abdullah M, O’Donoghue M, Campbell L, Wickremasinghe MI, Lalvani A, Kon OM, Khan SA. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol 2015; 21(29): 8920-8926 [PMID: 26269682 DOI: 10.3748/wjg.v21.i29.8920] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
643 Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong C, Wong J, Lee K, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma: Meta-analysis: anti-viral therapy and HCC recurrence. Alimentary Pharmacology & Therapeutics 2011;33:1104-12. [DOI: 10.1111/j.1365-2036.2011.04634.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 10.5] [Reference Citation Analysis]
644 Herbers U, Amini-Bavil-Olyaee S, Mueller A, Luedde T, Trautwein C, Tacke F. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains. J Viral Hepat. 2013;20:141-148. [PMID: 23301549 DOI: 10.1111/j.1365-2893.2012.01639.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
645 Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011;4:55-64. [PMID: 21694909 DOI: 10.2147/idr.s4188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
646 Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, Fiore M, Sagnelli C, Pasquale G. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat. 2012;19:890-896. [PMID: 23121368 DOI: 10.1111/j.1365-2893.2012.01627.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
647 Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218-1229. [PMID: 20600036 DOI: 10.1053/j.gastro.2010.06.042] [Cited by in Crossref: 167] [Cited by in F6Publishing: 158] [Article Influence: 13.9] [Reference Citation Analysis]
648 Bottero J, Boyd A, Gozlan J, Carrat F, Lemoine M, Rougier H, Varsat B, Boo N, Charlois-Ou C, Collignon A. Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. Eur J Gastroenterol Hepatol. 2016;28:633-639. [PMID: 26954517 DOI: 10.1097/meg.0000000000000620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
649 Lei Z, Xia Y, Si A, Wang K, Li J, Yan Z, Yang T, Wu D, Wan X, Zhou W, Liu J, Wang H, Cong W, Wu M, Pawlik TM, Lau WY, Shen F. Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. J Hepatol. 2018;68:655-662. [PMID: 29155069 DOI: 10.1016/j.jhep.2017.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
650 Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
651 Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Review of Gastroenterology & Hepatology 2014;6:187-98. [DOI: 10.1586/egh.12.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
652 Feeney SA, Mccaughey C, Watt AP, Agnaf MRE, Mcdougall N, Wend UC, Gerlich WH, Coyle PV. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol 2013;85:597-601. [DOI: 10.1002/jmv.23513] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
653 Li Y, Zhang Y, Wang J, Lian J, Bai X. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. J Viral Hepat 2013;20:46-51. [DOI: 10.1111/jvh.12063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
654 Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93. [PMID: 27026375 DOI: 10.1007/s12072-016-9720-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
655 Vutien P, Trinh HN, Nguyen K, Garcia RT, Nguyen HA, Levitt BS, Nguyen L, Ha NB, Ahmed A, Daugherty T, Garcia G, Nguyen MH. Precore and basal core promoter mutations in Asian American patients with hepatitis B e antigen-positive chronic hepatitis B. Aliment Pharmacol Ther 2013;37:464-72. [PMID: 23278246 DOI: 10.1111/apt.12193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
656 Vermehren J, Lötsch J, Susser S, Wicker S, Berger A, Zeuzem S, Sarrazin C, Doehring A. A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers. PLoS One 2012;7:e32605. [PMID: 22448225 DOI: 10.1371/journal.pone.0032605] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
657 Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-8. [DOI: 10.1002/hep.22921] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
658 Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727-2734. [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
659 Juan J, Feld JJ. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Curr Opin Rheumatol. 2014;26:395-403. [PMID: 24841230 DOI: 10.1097/bor.0000000000000067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
660 Kahloun A, Bourlière M, Zoulim F. [Analogs combination therapy in chronic hepatitis B: when and how?]. Gastroenterol Clin Biol 2010;34 Suppl 2:S126-35. [PMID: 21095516 DOI: 10.1016/S0399-8320(10)70032-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
661 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
662 Lampertico P, Viganò M, Colombo M. Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. Curr Hepatitis Rep 2012;11:90-4. [DOI: 10.1007/s11901-012-0127-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
663 Zhou B, Liu M, Lv G, Zheng H, Wang Y, Sun J, Hou J. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays. J Viral Hepat. 2013;20:422-429. [PMID: 23647959 DOI: 10.1111/jvh.12044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
664 Jang BK. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Clin Mol Hepatol 2020;26:312-4. [PMID: 32646206 DOI: 10.3350/cmh.2020.0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
665 Peng Y, Li Y, Hou J, Sun J, Su M, Li Y, Xiang K, Yan L, Zhuang H, Li T. The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response. Infect Genet Evol 2017;49:116-21. [PMID: 28088502 DOI: 10.1016/j.meegid.2017.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
666 Rijckborst V, Janssen HL. The Role of Interferon in Hepatitis B Therapy. Curr Hepat Rep 2010;9:231-8. [PMID: 20949114 DOI: 10.1007/s11901-010-0055-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
667 Dong P, Zhang X, Zhao W, Ding H. HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report. Journal of Infection and Chemotherapy 2013;19:1188-92. [DOI: 10.1007/s10156-013-0602-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
668 Antaki N, Zeidane N, Alhaj N, Hadad M, Baroudi O, Antaki F, Abouharb R, Haffar S, Abdelwahab J, Alideeb S, Asaad F, Aljesri A, Doghman D, Aaraj R, Ibrahim N, Ali A, Assil M, Sabah H, Katranji N, Kebbewar K. HBsAg titers in the different phases of hepatitis B infection in Syrian patients. Journal of Clinical Virology 2012;53:60-4. [DOI: 10.1016/j.jcv.2011.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
669 Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239-44. [PMID: 20978862 DOI: 10.1007/s11606-010-1549-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
670 Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy. 2009;1:1053-1061. [PMID: 20635919 DOI: 10.2217/imt.09.59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
671 Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Journal of Hepatology 2009;51:640-6. [DOI: <